PF-06425090 ( Clostridium difficile Vaccine)
B5091007Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 1A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED 
STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND 
OLDER
Investigational Product Number: PF-06425090
Investigational Product Name: Clostridium difficile Vaccine
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2016-003866-14
Protocol Number: B5091007
Phase: 3
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes
Original protocol 28 October 2016 Not applicable (N/A)
Protocol amendment 1 26 January 2017 Following regulatory 
consultation:
•Rationalized objectives and 
endpoints.
•Clarified case definitions.
•Revised permissible timing 
for administration of nonadjuvanted seasonal or pandemic influenza vaccine.
•Added a Month 12 
telephone contact for collection of serious adverse events.
•Changed description of 
diagnostic methodology for detection of toxin.
•Added safety reporting 
requirements for studies employing medical devices.
•Updated statistical 
methodology to reflect changes in objectives and endpoints.
•Made minor editorial 
updates.
Protocol amendment 2 03 January 2019 In order to control overall Type 
I error and Type I error for the evaluation of the secondary objectives:
•Revised secondary  
 objectives and 
endpoints.
Following blinded case count 
review:
•Revised sample size.CCI
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 3Additionally :
Refined the parameters
collected for and included in
the healthcare resource 
utilization score.
Defined the mI TT-1 
population .
Included analy ses of the 
primary  endpoints for the 
m-ITT populations for cases 
occurring 14 day s after the 
second and third doses.
Made e ditorial updates to 
the Data Analy sis/Statistica l 
Methods s ection .
Incorporated a protocol 
administrative change to the 
medical device complaint 
reporting procedure .
Incorporated a protocol 
administrative change to 
clarify  that V isit 6 can be 
conducted in person .
Incorporated France -and 
Japan -specific appendices .
Protocol Amendment 3 06January 2020 Added the annual retention 
visit.
Added the requirement to 
reconsent subjects atthe
additional visit.
Extended the study  duration.
Protocol Amendment 4 28 Sept. 2020 Added the definition of an 
outpatient visit to inclusion 
criterion 4 .
Clarified sy stemic antibiotic 
use for the purposes of 
inclusion criterion 4 .
Added a reminder every  2 
weeks for all subject sto 
collect a stool sample should 
a diarrheal episode occur .
Clarified the requirement to
capture major protocol 
deviations .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 4Clarified that if a nSAE is 
reported after subject Visit 
6, all the requirements will 
apply , including the respect 
of the reporting timelines as 
if the SAE occurred within 
the reporting period .
Adjust edthe assumption f or 
vaccine efficacy andthe 
total cases required for the 
study ,introduced 
2additional interim 
analyses,and updated the 
statistical design operating 
characteristics accordingly .
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics committees 
(ECs).  
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 5TABLE OF CONTENTS
LIST OF TA BLES .....................................................................................................................9
LIST OF FIGURES ...................................................................................................................9
APPENDI CES ...........................................................................................................................9
PROTOCOL  SUMMARY .......................................................................................................11
SCHEDUL E OF ACTIVITI ES................................................................................................14
1. INTRODUCTION ...............................................................................................................17
1.1. Mechanism of Action/I ndication .............................................................................17
1.2. Background and Rationale
......................................................................................17
1.2.1. Clostridium difficile Disease Background ..................................................17
1.2.2. Clostridium difficile Vaccine Development Rationale ...............................18
1.2.3. Clostridium difficile Vaccine Candidate .....................................................19
1.2.3.1. Nonclinical Development ..........................................................19
1.2.3.2. Clinical Development ................................................................19
1.2.3.3. Summary  of Benefit -Risk Assessment ......................................21
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................22
2.1. CDI  Case Definitions ..............................................................................................26
2.1.1. D efinition 1 
–Primary  Episode ..................................................................26
2.1.2. Definition 2 
– Recurrent Episode ...............................................................26
2.1.3. Definition 3 
–Primary  Episode Diagnosed L ocally ...................................26
2.1.4. Definition 4 
–Recurrent Episode Diagnosed L ocally ................................27
3. STUDY DESIGN .................................................................................................................27
3.1. Approximate Number of Subjects ...........................................................................27
3.2. Approximate Duration of the Study ........................................................................28
3.3. Approximate Duration of Subject Participation
......................................................28
4. SUBJECT ELIGIBILI TY CRI TERIA ................................ ................................ ................. 28
4.1. I nclusion Criteria .....................................................................................................29
4.2. Exclusion Criteria ....................................................................................................30
4.3. Criteria for Temporarily  Delay ing Vaccine Administration ...................................31
4.4. L ifesty le Requirements ...........................................................................................32
4.4.1. Contraception ..............................................................................................32
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 64.5. Sponsor’s Qualified Medical Personnel ..................................................................33
5. INVESTIGAT IONAL P RODUCTS ...................................................................................33
5.1. Allocation to I nvestigational Product ......................................................................33
5.2. Blinding of Site Personnel .......................................................................................34
5.3. Blinding of the Sponsor
...........................................................................................34
5.4.Breaking the Blind ..................................................................................................34
5.5. Subject Compliance .................................................................................................34
5.6. Vacci ne Supplies .....................................................................................................35
5.6.1. Formulation and Packaging ........................................................................35
5.6.1.1. Clostridium difficile Vaccine ....................................................35
5.6.1.2. Placebo ......................................................................................35
5.6.2. Preparati on and Dispensing ........................................................................35
5.6.3. Administration ............................................................................................35
5.7. I nvestigational Product Storage ..............................................................................36
5.8. I nvestigational Product Accountabilit y
...................................................................37
5.8.1. Destruction of Investigational Product Supplies
........................................37
5.9. Concomitant Medication(s) .....................................................................................37
5.9.1. Recording Concomitant Vaccinations and Medications
.............................37
5.9.2. Prohibited Concomitant Vaccinations and Medications
.............................38
5.9.3. Permitted Concomitant Medications
..........................................................38
6. STUDY PROCEDURES
.....................................................................................................38
6.1. Study  Period ............................................................................................................38
6.1.1. Visit 1: Month 0 
–Vaccination 1 ...............................................................39
6.1.2. Visit 2: Month 1 
–Vaccination 2 (28 to 42 Day s After Visit 1) ................ 41
6.1.3. Visit 3: Month 2 (28 to 42 Day s After Visit 2) ...........................................42
6.1.4. Visit 4: Month 6 
–Vaccination 3 (140 to 168 Day s After Visit 2) ............43
6.1.5. Visit 5: Month 7 (28 to 42 Day s After Visit 4) ...........................................45
6.1.6. Visit 6: Month 12 (165 to 195 Day s After Visit 4) .....................................46
6.1.7. Annual Retention Visits (Every  280 to 392 Day s After Visit 5) ................46
6.1.8. Visit 7: End of Study ..................................................................................47
6.1.9. At the Time of a Potential CDI  Case (Follow -
up Related to Each 
Diarrheal Episode) ................................ ................................ ........................... 47
PF-06425090 ( Clostridium difficile Vaccine)
B5091007Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 76.1.10. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction............48
6.2. Subject Withdrawal .................................................................................................49
6.2.1. Major Protocol Violations ..........................................................................49
6.3. Stool Sample Collection..........................................................................................506.4. Subject Communication and Use of Technology....................................................50
7. ASSESSMENTS................................................................................................................. .51
7.1. Efficacy Assessments..............................................................................................51
7.1.1. Central Laboratory Testing for Clostridium difficile ..................................51
7.1.1.1. Detection of Toxigenic Clostridium difficile by PCR...............52
7.1.1.2. Detection of Free Toxins in the Stool Sample ..........................52
7.1.2. Diagnosis of Pseudomembranous Colitis ...................................................52
7.2. Safety Assessments .................................................................................................52
7.2.1. Electronic Diary..........................................................................................53
7.2.1.1. Grading Scales...........................................................................537.2.1.2. Local Reactions .........................................................................537.2.1.3. Systemic Events ........................................................................547.2.1.4. Fever..........................................................................................55
7.4. Other Assessments ..................................................................................................56
7.5. Pregnanc y Testing ...................................................................................................56
8. ADVERSE EVENT REPORTING......................................................................................57
8.1. Requirements...........................................................................................................57
8.1.1. Additional Details on Recording Adverse Events on the CRF...................588.1.2. Eliciting Adverse Event Information..........................................................588.1.3. Withdrawal From the Study Due to Adverse Events (see also the 
Subject Withdrawal section)............................................................................58
8.1.4. Time Period for Collecting AE/SAE Information......................................59
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................598.1.4.2. Recording Nonserious AEs and SAEs on the CRF...................59
8.1.5. Causality Assessment .................................................................................59
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................60CCI
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 88.2. Definitions............................................................................................................... 60
8.2.1. Adverse Events ...........................................................................................608.2.2. Abnormal Test Findings .............................................................................618.2.3. Serious Adverse Events ..............................................................................618.2.4. Hospitalization............................................................................................62
8.3. Severity Assessment................................................................................................648.4. Special Situations ....................................................................................................64
8.4.1. Protocol-Specified Serious Adverse Events ...............................................648.4.2. Potential Cases of Drug-Induced Liver Injury............................................648.4.3. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................66
8.4.3.1. Exposure During Pregnancy......................................................668.4.3.2. Exposure During Breastfeeding ................................................678.4.3.3. Occupational Exposure .............................................................67
8.4.4. Medication Errors .......................................................................................68
8.4.4.1. Medication Errors......................................................................68
8.5. Medical Device Complaint Reporting Requirements .............................................69
9. DATA ANALYSIS/STAT ISTICAL METHODS...............................................................69
9.1. Sample Size Determination.....................................................................................699.2. Efficacy Analysis ....................................................................................................71
9.2.1. Analysis of the Primary Endpoints.............................................................71
9.2.1.1. Multiplicity Control for the Primary Endpoints........................73
9.2.2. Analysis of the S econdary Endpoints.........................................................73
9.2.2.1. Analysis of the Seconda ry Efficacy Endpoints .........................73
9.4. Safety Analysis........................................................................................................74
9.4.1. Reactogenicity ............................................................................................75
9.5. Interim Analysis ......................................................................................................759.6. Data Monitoring Committee ...................................................................................78
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................7811. DATA HANDLING AND RECORD KEEPING .............................................................79
11.1. Case Report Forms/Electronic Data Record .........................................................79
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 911.2. Record Retention ...................................................................................................80
12. ETHI CS..............................................................................................................................80
12.1. I nstitutional Review Board/Ethics Committee ......................................................80
12.2. Ethical Conduct of the Study ................................................................................80
12.3. Subject I nformation and Consent ..........................................................................80
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................81
13. DEFINITION OF EN D OF TRIAL ...................................................................................81
13.1. End of Trial in a Member State
.............................................................................81
13.2. End of Trial in All Other Participating Countries .................................................81
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................82
15. PUBLICATION OF S TUDY RESUL TS..........................................................................82
15.1. Communication of Results by  Pfizer ....................................................................82
15.2. Publications by  Investigators ................................................................................83
16. REFERENCES ..................................................................................................................84
LIST OF TABLES
Table 1. Intended Numbers of Subjects Included in the Study , by Age ................. 27
Table 2. Cepheid Xpert C. difficile /EpiResults......................................................52
Table 3. Local Reaction Grading Scale ..................................................................54
Table 4. Systemic Event Grading Scale ..................................................................54
Table 5. Scale for Fever ..........................................................................................55
Table 6. Statistical Analy sis Specifications for the Primary  Endpoints .................72
Table 7. Statistical Design Operating Characteristics ............................................77
LIST OF FIGURES
Figure 1. Two-Step Testing Algorithm for Determination of Clostridium 
difficile Infection Case Definition ............................................................51
APPENDICES
Appendix 1. Abbreviations ................................ ................................ ................................ ......90
Appendix 2. Bristol Stool Chart...............................................................................................92
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 10Appendix 3. France Appendix .................................................................................................93
Append ix4. Japan Appendix
...................................................................................................94
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 11PROTOCOL SUMMARY
Indication
Pfizer’s investigational Clostridium difficile vaccine (PF -06425090) is a prophy lactic vaccine 
that is currentl y being investigated for the prevention of primary C difficile infection (CDI) in 
adults 50 y ears of age and older.
Objectives and 
Endpoints
Primary Efficacy Objective(s): Primary Efficacy En dpoint(s):
To demonstrate that Pfizer’s C difficile vaccine is 
effective in reducing the incidence of a first primary 
episode of CDI (see case definition 1).aCDI incidence per 1000 person -years of follow -up, 
assessed during up to 2time periods (each analysis 
will be performed only if the preceding one was 
successful):
 After receipt of the third dose of investigational 
product onwards.
 After receipt of the second dose of 
investigational product onwards.
Primary Safety Objective(s): Primary Safety Endpoint(s):
To evaluate the safety profile of Pfizer’s C difficile
vaccine as measured by the percentage of subjects 
reporting local reactions and systemic events, adverse 
events (AEs),and serious adverse events (SAEs) .Local reactions (pain, erythema, and induration), as 
self-reported on electronic diaries ( e-diaries )for up to 
7days following each dose of investigational product .
Systemic events (fever, vomiting, headache, fatigue, 
new or worsening muscle pain, and new or worsening 
joint pain), as self -reported on e -diaries for up to 7 
days following each dose of investigational product .
Nonserious AEs from signing of the informed consent 
document (ICD) to 1month after receipt of thethird 
dose of investigational product .
SAEs from signing of the ICD to 6month safter 
receipt of the third dose of investigational prod uct.
a. Each subject may contribute only once to the primary endpoint.
Study Design
This is a Phase 3, placebo- controlled, randomized, observer -blinded study  to evaluate the 
efficacy , safety, and tolerability  of aluminum hy droxide (AlOH) -containing C difficile
vaccine ( 200µg total toxoid) administered as a 3 -dose regimen at Months 0, 1, and 6 in 
adults 50 y ears of age and older.
Subjects will be randomly assigned in parallel in a 1:1ratio t o receive 
C difficile vaccine 
(200 µg total toxoid) or placebo (saline).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 12This is an event -driven study with a total target of 66 first primary  CDI cases (meeting case 
definition 1 in the per-protocol - 3 population); the total enrollment number may  vary  
depending on the incidence rate of the primary  endpoint, true underl ying vaccine efficacy  
(VE) ,and potential earl y stop for efficacy  or futility .
Investigational Products
Clostridium difficile Vaccine
The investigational Cdifficile vaccine is toxoid based. C difficile toxin A and toxin B are 
inactivated b y a combination of genetic mut ations and chemical treatments. The vaccine is 
provided as a sterile ly ophilized powder in a dosage strength of 200µg/dose (total for 
toxoi dsA and B). The vaccine will be reconstituted with AlOH diluent immediately  before 
use as instructed in the investigational product (IP) manual . The AlOH diluent is supplied as 
a 1-mg aluminum/mL  (as AlOH ) liquid suspension.
Placebo
The placebo will con sist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection, in a 0.5 -mL dose) and will be provided by  the sponsor to each study  site.
Statistical Method s
The VE is defined as VE = 100 × (1 –IRR), where I RR is the infection rate ratio, the 
calculated ratio of first primary  CDI incidence between the C difficile vaccine group and the
placebo group.  
Three (3)formal interim anal yses areplanned to check both efficacy  and futility  after 30, 40
and 50cases of first primary  CDI have occurred from 14 day s after receipt of the third dose 
of investigational product .Only theprimary  efficacy  endpoints will be examined during 
theseinterim anal yses. 
With 30 cases of first primary  CDI at the first planned interim anal ysis, if there are 6or fewer 
cases observed in the C difficile vaccine group, the null hy pothesis (H03)will be rejected ,the 
Cdifficile vaccine will be deemed efficacious ,and a full anal ysis of the data will be 
conducted . If there are 11or more cases observed in the Cdifficile vaccine group, futility  
may be declared
,and the study  may  be terminated.
With 40 cases of first primary CDI at the second planned interim anal ysis, if there are 9or 
fewer cases observed in the C difficile vaccine group, the null hy pothesis 
(H03) will be 
rejected ,the Cdifficile vaccine will be deemed efficacious ,and a full analy sis of the data 
may be conducted . If there are 13 or more cases observed in the Cdifficile vaccine group, 
futility  may  be declared, and the study  may  be terminated .
With 50 cases of first primary CDI at the third planned interim anal ysis, if there are 13or 
fewer cases observed in the C difficile vaccine group, the null hy
pothesis (H 03) will be 
rejected ,the Cdifficile vaccine will be deemed efficacious ,and a full analy sis of the data 
may be conducted .If there are 16 or more cases observed in the Cdifficile vaccine group, 
futility  may  be declared, and the study  may  be terminated .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 13If the stud y continues after 3 interim anal yses, for the final anal ysis, the primary  objective 
will have been met if there are 20 or fewer cases observed in the C difficile vaccine group out 
of a total of 66first primary  cases from 14 day s after receipt of the third dose of 
investigational product onward s.
AEs will be summarized using 3 -tier methodo logy.Local reactions and s ystemic events will 
be summarized.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 14SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the Study  Procedures and 
Assessments sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the schedule of activities table , in order to 
conduct evaluations or assessments required to protect the well -being of the subject.
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Annual 
Retention 
VisitVisit 7 At Time of 
Potential 
CDI CaseVisit Description Month 0
(Vax 1)Month 1
(Vax 2)Month 2 Month 6
(Vax 3)Month 7 Month 12 End of 
Study
Visit Window (Days) 1 28-42 Days 
After Visit 
128-42 Days 
After Visit 
2140- 168 
Days After 
Visit 228-42 Days 
After Visit 
4165-195
Days After 
Visit 4Every 280 -
392 Days 
After 
Visit 5aNot 
Applicable
Informed consentb X Xc
Dem ographyb X
Clinical assessment, including 
medical historybX
Record nonstudy vaccinationsdX X X X X
Record specified concomitant 
medicationsX
Measure and record height and 
weightbX
Oral temperaturebX X X
Urine pregnancy test (females of 
childbearing potential)bX X X
Discuss contraceptive usedX X X X
Confirm eligibilitydX X X X
Revie w temporary  delay criteriab X X X
RandomizationbX
Blood draw  for immunogenicity 
assessmentdX X X Xe
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 15Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Annual 
Retention 
VisitVisit 7 At Time of 
Potential 
CDI CaseVisit Description Month 0
(Vax 1)Month 1
(Vax 2)Month 2 Month 6
(Vax 3)Month 7 Month 12 End of 
Study
Visit Window (Days) 1 28-42 Days 
After Visit 
128-42 Days 
After Visit 
2140- 168 
Days After 
Visit 228-42 Days 
After Visit 
4165-195
Days After 
Visit 4Every 280 -
392 Days 
After 
Visit 5aNot 
Applicable
Vaccination X X X
Postvaccination observation (at least 
30 minutes) and AE assessmentX X X
Revie w stool sample collection and 
shipping instructions with the subject 
and ensure understandingX X X X X X X
Issue or send a stool collection kit 
and shipping box, and provide 
instructions on their use, as requiredX X X X X X X
Issue measuring device, and 
thermometer and provide instructions 
on their use, as requiredX X X
Revie w subject communication 
methods (including for e- diary 
completion), assist the subject w ith 
downloading the app, or issue 
provisioned device, if requiredX X X X X X X
Record AEs X X X X XfXf
Record SAEs X X X X X X
Capture major protocol violations X X X X X X X X
Telephone contact visit XgX X
Electronic reminders
Telephone contact for subjects 
unresponsive to electronic reminders
Provision of stool sample X
Com pletion of diarrheal episode 
questionnaireX
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 16Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Annual 
Retention 
VisitVisit 7 At Time of 
Potential 
CDI CaseVisit Description Month 0
(Vax 1)Month 1
(Vax 2)Month 2 Month 6
(Vax 3)Month 7 Month 12 End of 
Study
Visit Window (Days) 1 28-42 Days 
After Visit 
128-42 Days 
After Visit 
2140- 168 
Days After 
Visit 228-42 Days 
After Visit 
4165-195
Days After 
Visit 4Every 280 -
392 Days 
After 
Visit 5aNot 
Applicable
Subject completes e -diary X X X
Revie w e-diary data 
Abbreviations: CDI = Clostridium difficile infection; e -diary = electronic diary; Vax = vaccination; = ongoing/continuous event.
a.Follow ing approval of Amendment 3, subjects already enrolled in the study should have an annual retention visit arranged at the earliest opportunity, and 
then every 280 to 392 days thereafter.
b.Prior to vaccination.
c.At the first annual retention visit or potential CDI visit ,whichever occurs first .
d.Prior to vaccination, if at a vaccination visit.
e.Optimally within 48 hours of t he third unformed stool (Bristol stool chart types 5 -7).
f.Any AEs occurring up to 48 hours after each blood draw  must be recorded.
g.Visit is intended to be conducted by telephone but, if desired, may be conducted in person.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 171.INTRODUCTION
1.1. Mechanism of Action/ Indication
Pfizer’s investigational Clostridium difficile vaccine (PF -06425090) is a prophy lactic vaccine
that is currentl ybeing investigated for the prevention of primary  C difficile infection (CDI) in 
adults 50 y ears of age and older .
1.2.Background and Rationale
1.2.1. Clostridium difficile Disease Background
C difficile , a gram -positive anaerobic, spore -forming bacillus, is the main cause of 
nosocomial infectious diarrhea in industrialized countries.1,2,3,4,5  It accounts for 20% to 30% 
of cases of antibiotic
-associated diarrhea and is the most commonly  recognized cause of 
infectious diarrhea in healthcare settings.6  C difficile is carried in approximately  3% of 
healthy  adults and approximately  16% to 35% of hospital inpatients; among the latter the rate 
increases with exposure to antibiotics.7  As many  as 50% or more of hospital patients 
colonized by  C difficile are as ymptomatic carriers .6
C difficile can produce 3 toxins, toxin A (TcdA), toxin B (TcdB) ,and binary  toxin.8  TcdA 
and TcdB are the principal virulence factors for CDI,9causing severe inflammation in the 
bowel.10
,11  The spectrum of CDI ranges from as ymptomatic colonization and mild 
self-limiting diarrhea, to more serious complications such as severe diarrhea, 
pseudomembranous colitis, toxic megacolon, intestinal perforation, and death .2,12
Individuals with mild to moderate CDI may  experience diarrhea 3 or more times a day  for 2 
or more day s, along with mild abdominal cramping and tenderness.  However, individuals 
with a severe infection may  experience watery  diarrhea 10 to 15 times a day , abdominal 
cramping and pain thatmay be severe, fever, blood or pus in the stool, nausea, dehy dration, 
loss of appetite, weight loss, swollen abdomen, kidney  failure, and i ncreased white blood cell 
count.13
The main risk factors for an initial episode of CDI are antibiotic therap y, prolo nged 
hospitalization, and severe comorbidities.  Older adults (>65 y ears of age) are at an increased 
risk for CDI, particularl
y when exposed to healthcare settings.11,14,15,16,17  Although most 
patients experiencing a first episode of CDI respond well to standard antibiotic treatment, 
approximately  15% to 3
5% of patients suffer from at least 1 recurrence.11,18,19  Additional 
risk factors for recurrence include failure to mount an immune response to TcdA and/or 
TcdB and infection with a hy pervirulent strain.20
,21
Increased incidence and severit y of the disease with associated complications, colectomy 
rates, and mortalit y have been observed over the last 10 to 20 y ears.22,23,24  In Europe, 
increased mortality
, prolonged length of hospital stay , and incremental cost of hospitalization 
in association with CDI  have been reported.25,26  A systematic review published in 2012 
reported 30
-day mortality  estimates in Europe ranging from 6.8% to 42%.26  In a surveillance 
study  conducted in the United States, approximately  453,000 cases of CDI and
approximately  29,000 deaths were reported in 2011.27
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 18Based on data reported from acute care facilities, the cost of caring for patients experiencing 
CDI in the United States ranges from $ 1.1 to $4.8 billion annually .28,29
In the last decade, the numbers and severity  of C difficile iatrogenic outbreaks in hospitals 
and nursing homes have increased.27,28,30  Key  factors in this escalation include emergence of 
hypervirulent pathogenic strains such as BI/NAP1/027,31,32,33increased use of antibiotics,34
improved detection methods, and increased exposure to spores in healthcare facilities.35
Metronidazole has been recommended as initial therapy  since the late 1990s and continues to 
be the first choi ce for all but seriously  ill patients and those with complicated or fulminant 
infections or multiple recurrences of CDI, for whom vancomy cin is recommended.6,21,36  
Fidaxomicin has been developed more recently  and has been shown to be noninferior to 
vancom ycin for treatment of CDI .  In addition, treatment with fidaxomicin was associated 
with a significantly  lower rate of recurrence than was treatment with vancomy cin
.19
European guidelines for treatment of CDI include fidaxomicin as an option for treatment of 
recurrence.21  Fecal transplantation has also been shown to be effective in some patients for 
the treatment of multiple recurrences of CDI.37
,38  However, regulatory  oversight of this 
method remains in development,39and, therefore, a highl y effective noninvasive treatment 
for complicated CDI does not exist.
To date ,the onl y measures available to help prevent CDI  are behavioral ones such as 
encouraging appropriate use of antimicrobials, use of contact precautions, and cleaning and 
disinfection of equipment and the environment.40
1.2.2. Clostridium difficile Vaccine Development Rationale
It iswell established that humoral immune responses to C difficile toxins play a significant 
role in preventing a more severe outcome or a recurrence of the disease in humans.  Several 
clinical studies suggest a correlation between high serum concentrations of antitoxin A and B 
immunoglobulin G (IgG) (as measured b y enz yme
-linked immunosorbent assay  [ELISA])
and protection from CD Ior recurrence after primary  CDI.20,41,42,43Preclinical studies have 
shown t hat active immunization with inactivated toxins (“toxoids”) and passive 
immunization with antitoxin antibodies protect animals from lethal challenge.44,45,46  
Furthermore, a Phase 2 trial with monoclonal antibodies (mAbs) designed to neutralize TcdA
and TcdB provides clinical evidence supporting a role for antitoxin antibodies in the 
prevention of CD Irecurrences.47Systemic administration of a combination of 2 neutralizing 
human mAbs against TcdA and TcdB was associated with fewer recurrences than placebo 
(7% versus 25% recurrences, respectivel y; p<0.001).  These results were confirmed in 2 
Phase 3 studies.  In both studies, results showed that the rate of recurrence of CDI was 
significantl y lower when the mAb against TcdB (bezlotoxumab) was administered, whether 
on its own or in combination with the mA b against TcdA (actoxumab), compared with 
placebo.48  Finally , another group demonstrated that a combination of 2 mAbs directed 
against different ep itopes from the binding domain of TcdA was significantly  more potent in 
neutralizing the toxin in vitro than a single mAb.49  Furthermore, while the TcdA and TcdB 
amino acid sequences are generall y well conserved within the same sequence t ypes, there is 
high variation between sequence ty pes,50indicating that a pol yclonal antibody approach, 
such as elicited b y active immunization with C difficile toxoids, may  be more efficacious to 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 19prevent primary  and recurrent CDI.  Taken together, these findings provide the rationale for 
the development of a C difficile toxoid -based vaccine to prevent CD I that includes both TcdA 
and TcdB.  Pfizer therefore is developing a bivalent vaccine composed of both toxoids to 
elicit br oad antitoxin immunity  against TcdA and TcdB.
To date, there is no approved vaccine to prevent primary  or recurrent CDI.  There are at least 
2 other vaccines in development that target C difficile toxins.  A toxoid- based vaccine 
adjuvanted with aluminum hy droxide (AlOH) has been evaluated in Phase 1 and 2 
studies,51,52,53,54and efficacy  is currently  being evaluated in a Phase 3 study .55  The other is a 
recombinant fusion protein comprisi ng fragments of the receptor -binding domains of TcdA
and TcdB separated b y a 4–amino acid linker ;56this vaccine hasbeen evaluated in a
completed Phase 2 study .57
The increasing burden of CDI  on patients and on the healthcare s ystem demonstrates that 
prevention of CDI constitutes a significant unmet medical need.
1.2.3. Clostridium difficile Vaccine Candidate
Pfizer’s C difficile vaccine candidate consists of a 1:1 mixture of C difficile toxoids A and B.  
The toxoids were derived from native toxins by  genetic modification to decrease toxin 
activity , and chemical inactivation prior to final purification and formulation of the drug 
substance.
1.2.3.1.
Nonclinical Development
In nonclinical experiments, Pfizer’s C difficile candidate vaccine was studied either alone or 
in combination with AlOH.  Using the standard hamster C difficile disease model, vaccine 
formulations with and without AlOH demonstrated a survival benefit, providing at least 90% 
protection from a lethal challenge with C difficile spores in the immunized hamsters.  In 
addition, pooled sera obtained from hamsters immunized with the C difficile vaccine 
formulated with AlOH neutralized secreted toxins from C difficile isolates representing 
diverse ribot ypes/pulsed -field gel electrophoresis (PFGE) t ypes, including hypervirulent 
strains, and covering >67% and >70% of the circulating strains in the U nited States and 
Europe, respectivel y.Furthermore, in nonhuman primates, Pfizer’s toxoid vaccine 
formulations with and without AlOH induced robust neutralizing antitoxin antibody  
responses to both TcdA and TcdB.  The nonclinical data generated b y Pfizer in rhesus 
macaques support the use of a 3 -dose regimen of the 
C difficile vaccine, with or without 
AlOH.
1.2.3.2. Clinical Development
The B5091001 first -in-human study  was a placebo -controlled, randomized, observer -blinded 
Phase 1 study  that evaluated the safet y, tolerability, and immunogenicit y of Pfizer’s 
Cdifficile vaccine.  Three (3)antigen dose levels (50, 100, and 200 g) were assessed and 
administered either alone or in combination with AlOH at Months 0, 1,and 6 to healthy  
adults 50 to 85 y ears of age.58Overall, the 
C difficile vaccine formulations and dose levels 
administered were generally  well t olerated.  Local reactions and s ystemic events were 
predominantly  mild to moderate, were more common in the 50 -to 64-year age cohort, and 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 20comprised mostly  injection site pain, headache, and fatigue.  Adverse events (AEs) were 
reported in all vaccine group s, with little difference in the number of subjects between the 
dose groups and the placebo group or between vaccine formulations.  In subjects who 
received the vaccine formulations, both the toxin A– and toxin B –specific neutralizing 
antibody  geometric me an concentrations increased substantially  at 1 month after Dose 2 and 
after Dose 3 compared to baseline.  In the 50 -to 64-year age cohort, geometric mean fold 
rises (GMFRs) in toxin A
–specific neutralizing antibodies from baseline at Month 7 ranged 
from 59.19 to 149.23 in the dose groups compared to 2.47 in the control group.  For 
toxin B–specific neutralizing antibodies, the GMFRs from baseline at Month 7 ranged from 
116.67 to 2503.75 in the 
dose groups compared to 2.48 in the control group.  I n the 65 -to 
85-year age cohort, the GMFRs in toxin A –specific neutralizing antibodies from baseline at 
Month 7 ranged from 42.73 to 254.77 in the dose groups compared to 2.03 in the control 
group.  For toxin B
–specific neutralizing antibodies, the GMFRs from bas eline at Month 7 
ranged from 136.12 to 4922.80 in the dose groups compared to 1.58 in the control group.  
Potent antitoxin neutralizing responses were still evident in immunized subjects in both age 
groups at Month 12.  Although there was no clear dose -lev
el response pattern, the data 
suggest that both the antitoxin A –and antitoxin B–specific neutralizing responses were 
trending higher in the toxoid -only groups compared to the toxoid + AlOH groups.  
Furthermore, the magnitude of the immune response was sim
ilar in the 2 age cohorts.
Based on these data, a Phase 2 study  (B5091003) was initiated using a 3 -dose regimen 
(Day s 1, 8, and 30) and 2 antigen dose levels (100 and 200 g) of the toxoids alone 
reconstituted with sodium chloride diluent.  However, recrui tment and vaccinations were 
halted 
because of the occurrence of 7 cases of Grade 3 injection site redness after Dose 2.  In 
light of this observed tolerability  profile, the decision was made to progress development of 
the AlOH -containing formulation into a second Phase 2 study . This Phase 2 study  
(B5091009) of the AlOH -containing formulation is ongoing to assess the safety , tolerability , 
and immunogenicit y of 2 antigen dose levels (100 and 200 g) and two 3- dose regimens 
(Day s 1, 8, and 30 and Months 0, 1, and6).  Aprespecified interim analy sis of data up to 
Month 7 from this study  demonstrated that the immunogenicit y profile following 3 doses 
administered at Months 0, 1, and 6 was superior to that when the doses were administered at 
Days 1, 8, and 30. In addition, the 200 -g dose level was more immunogenic than the 
100-g dose level. On this basis, it was decided to progress into Phase 3 development with 
the 
200-g dose level administered at Months 0, 1, and6.
The present study (B5091007) is therefore a placebo -controlled, randomized ( 1:1, 
vaccine:placebo), observer -blinded, parallel- group study  in up to approximately  17,476
subjects 50 y ears of age or older who have an increased risk of CDI . In the absence of an 
accepted immunological correlate of pr otection for CDI, vaccine efficacy  (VE) will be 
determined b y comparing the CDI incidence in recipients of the investigational vaccine with 
those receiving placebo. Any time during the study  period that a subject experiences passage 
of 3 or more unformed stools (Bristol stool chart ty pes 5 -
7;see Appendix 2)59within 24 
hours, the subject will be asked to collect the third or subsequent stool for provision to the 
central laboratory . 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 21Stool specimens will be tested at a central laboratory  for presence of the C difficile organism 
and TcdA/TcdB. The study  is designed to accrue 66first primary  CDI cases, meeting case 
definition 1 ( Section 2.1.1 ),occurring from 14 day s after the third dose of vaccine.
1.2.3.3. Summary of Benefit -Risk Assessment
C difficile is the main cause of nosocomial infectious diarrhea in industrialized 
countries.1,2,3,4,5  It accounts for 20% to 30% of cases of antibiotic -associated diarrhea and is 
the most commonly  recognized cause of infectious diarrhea in healthcare settings.6  To date, 
there is no approved vaccine to prevent primary  or recurrent CDI.  The increasing burden of 
CDI on patients and on the healthcare s ystem demonstrates that pr evention of CDI 
constitutes a significant unmet medical need.
The B5091001 first -in-human study , which assessed 3 antigen dose levels (50, 100 ,and 
200g) administered either alone or in combination with AlOH at Months 0, 1,and 6 to 
healthy  adults 50 to 85 years of age, demonstrated that the 
C difficile vaccine formulations 
and dose levels administered were generally  well tolerated.  Local reactions and sy stemic 
events were predominantly mild to moderate, and comprised mostly injection site pain, 
headache , and fatigue. There was little difference in the number of subjects reporting AE s 
between the 
dose groups and the placebo group or between vaccine formulations.
The B5091009 Phase 2 study , which assessed 2 antigen dose levels (100 and 200 g) 
administered in combination with AlOH at Months 0, 1, and 6 or Day s 1, 8 ,and 30 to health y 
adults 65 to 85 y ears of age, demonstrated that both regimens and both dose levels 
administered were generally  well tolerated. Local reactions were predominantly  mild to 
moderate, with injection site pain being the most frequent manifestation. After D ose 2, local 
reactogenicity  was greater when the vaccine was administered at Day  8 compared to 
Month 1, particularl y for the 200- g dose level. Systemic events were a lso predominantly  
mild to moderate and the incidences of individual events were similar between the placebo
group , the 100-g dose group ,and the 200- g dose group. Within each regimen, the overall 
AEincidence rates were also similar between the placebo, 100- g,and 200 -g dose groups. 
For both regimens, s erious adverse events (SAEs) 
were numericall y higher in the 100 -g and 
200-g dose groups than in the placebo group. However, there was no pattern to these 
events and no safet y concern was identified. Both studied dose levels resulted in substantial 
neutralizing antitoxin A and B titers, with the immunogenicit y profile following 3 doses 
administered at Months 0, 1, and 6 being preferred.   In addition, the 200 -g dose level was 
more immunogenic than the 100 g dose level.
Pfizer 
considers the available information from Studies B5091001 and B5091009 with 
PF-06425090 to support a favorable benefit -risk profile for studies administ ering 3 doses of 
the C difficile vaccine at dose levels up to 200 µg formulat ed with AlOH, as a potential 
prevention against CDI.
Additional information for this compound may  be found in the single reference s afety 
document (SRSD) , which for this study  is the investigator ’sbrochure (IB).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 222. STUDY OBJECTIVES AND ENDPOINTS
Primary Efficacy Objective(s): Primary Efficacy Endpoint(s):
To demonstrate that Pfizer’s C difficile vaccine is 
effective in reducing the incidence of a first primary 
episode of CDI (see case definition 1).aCDI incidence per 1000 person -years of follow -up, 
assessed during up to 2time periods (each analysis 
will be performed only if the preceding one was 
successful):
 After receipt o f the third dose of investigational 
product onwards.
 After receipt of the second dose of 
investigational product onwards.
Primary Safety Objective(s): Primary Safety Endpoint(s):
To evaluate the safety profile of Pfizer’s C difficile
vaccine as measured by the percentage of subjects 
reporting local reactions and systemic events, AEs, and 
SAEs.Local reactions (pain, erythema, and induration), as 
self-reported on electronic diaries (e -diaries) for up to 
7 days following each dose of in vestigational product.
Systemic events (fever, vomiting, headache, fatigue, 
new or worsening muscle pain, and new or worsening 
joint pain), as self -reported on e -diaries for up to 7 
days following each dose of investigational product.
Nonserious AEs from the signing of the informed 
consent document (ICD) to 1 month after receipt of 
the third dose of investigational product.
SAEs from the signing of the ICD to 6month safter 
receipt of third dose of investigational product.
Evaluation 
OrderSecondary Objective(s): Secondary Endpoint(s):
3-Dose Family
1.  To evaluate the efficacy of Pfizer’s 
Cdifficile vaccine in reducing:
The incidence of all CDI cases
(see case definition 1 and case 
definition 2). CDI incidence per 1000 person -years of follow -up, 
assessed after receipt of the third dose of 
investigational product onwards.
2.  To evaluate the efficacy of Pfizer’s 
Cdifficile vaccine in reducing the 
severity of CDI, defined by:
The duration of CDI episodes.
The requirement to seek medical 
attention. Mean time to resolution of diarrhea in first primary 
episodes of CDI (case definition 1 ).
 Proportion of subjects experiencing a first primary 
episode of CDI (case definition 1 ) who have a non–
protocol-related medically attended visit during the 
CDI episode.
(Each analysis will be performed only if the 
preceding one was successful ).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 233. • To evaluate the efficacy of Pfizer’s 
C difficile vaccine in reducing the 
incidence of recurrent CDI (see case 
definition 2 ).• CDI incidence per 1000 person-years of follow-up, 
assessed after receipt of the third dose of investigational product onwards.
At-Least-2-Dose/Only-2-Dose Family
1.b • To evaluate the efficacy of Pfizer’s 
C difficile vaccine in reducing: 
• The incidence of all CDI cases 
(see case definition 1 and case 
definition 2 ).• CDI incidence per 1000 person-years of follow-up, 
assessed after receipt of the second dose of investigational product onwards.
2.b • To evaluate the efficacy of Pfizer’s 
C difficile vaccine in reducing the 
incidence of recurrent CDI (see case definition 2 ).• CDI incidence per 1000 person-years of follow-up, 
assessed after receipt of the second dose of investigational product onwards.
3.c • In subjects who receive only 2 doses of 
vaccine, to evaluate the efficacy of 
Pfizer’s C difficile vaccine in reducing:
•The incidence of a first primary 
episode of CDI 
(see case definition 1 ).
•The incidence of recurrent CDI 
(see case definition 2 ).• CDI incidence per 1000 person-years of follow-up.
(Each analysis will be performed only if the 
preceding one was successful).
 
 
 
 
 
 
  
 
 CCI
CCI CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 24 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 CCI CCI
CCI CCI
CCI CCI
CCI CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 25 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
a. Each subject may contribute only once to the primary endpoint.
b. At-least-2-dose family.c. Only-2-dose family.
Immunogenicity samples will also be collected during the study. All subjects with a first 
primary episode of CDI (meeting case definition 1, Section 2.1.1 ) will be matched with 1 or 
more control subjects; a separate analysis may be conducted on these case-control data to ascertain if it is possible to determine an immunological correlate of protection.CCI CCI
CCI CCI
CCI CCI
CCI CCI
CCI CCI
CCI CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 262.1. CDI Case Definitions
For all definitions, an episode will be considered to have resolved once there have been at 
least 2 days without passage of 3 or more unformed stools (Bristol stool chart types 5-7) and there is no further need for antibiotic treatment for CDI.
2.1.1. Definition 1 – Primary Episode
A primary episode of CDI (ie, no previous CDI onset in the prior 8 weeks) is defined as 
either:
•Presence of diarrhea, defined as passage of 3 or more unformed stools (Bristol stool chart 
types 5-7) in 24 or fewer consecutive hours; and
•Stool sample that is positive for the toxin B gene (by PCR) and positive for toxin A 
and/or toxin B, as measured in the central laboratory.
or:
•Pseudomembranous colitis diagnosed at colonoscopy, at surgery, or histopathologically; 
and corresponding stool sample that is positive for the toxin B gene (via PCR) as measured in the central laboratory.
2.1.2. Definition 2 – Recurrent Episode
An episode of CDI that occurs 8 weeks or less after the onset of a previous CDI episode 
(provided the symptoms of the previous episode had resolved), defined as either:
•Presence of diarrhea, defined as passage of 3 or more unformed stools (Bristol stool chart 
types 5-7) in 24 or fewer consecutive hours; and
•Stool sample that is positive for the toxin B gene (by PCR) and positive for toxin A 
and/or toxin B, as measured in the central laboratory.
or:
•Pseudomembranous colitis diagnosed at colonoscopy, at surgery, or histopathologically; 
and corresponding stool sample that is positive for the toxin B gene (by PCR) as measured in the central laboratory.
 CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 27 
 
3. STUDY DESIGN
This is a Phase 3, placebo-controlled, randomized, observer-blinded study to evaluate the 
efficacy, safety, and tolerability of AlOH-containing C difficile vaccine (200 μg total toxoid) 
administered as a 3-dose regimen at Months 0, 1, and 6 in adults 50 years of age and above.
Subjects will be randomly assigned in parallel in a 1:1 ratio to receive C difficile vaccine 
(200μg total toxoid) or placebo (saline).
This is an event-driven study with a total target of 66 first primary CDI cases (meeting case 
definition 1 in the per-protocol-3 population, Section 2.1.1 and Section 9.2.1 ) to be accrued 
for the study; the total enrollment number may vary depending on the incidence rate of the primary endpoint, true underlying VE, and potential early stop for efficacy or futility (seeSection 9.2 ).
3.1. Approximate Number of Subjects
It is anticipated that up to approximately 17,476 adults, 50 years of age and above, may be 
enrolled globally to accumulate 66 first primary CDI cases (meeting case definition 1, Section 2.1.1 ).  As this is an event-driven and group-sequential (GS) study, the final 
enrollment number may vary depending on the incidence rate of the primary endpoint, true underlying VE, and potential early stop for efficacy or futility. The number of subjects enrolled in each country and at each site will vary based on enrollment capabilities.
Update as Part of Amendment 2 (January 2019):
Based on the ongoing blinded review of pooled primary CDI events, it is planned to 
enroll approximately 1700 additional subjects, giving a total of approximately 17,476subjects (see Section 9.1) .
To achieve a broad representation of age groups among those 50 years and older, and achieve 
an adequate rate of CDI, the numbers of subjects intended to be enrolled in each of 4 age categories is shown in Table 1.
Table 1. Intended Numbers of Subjects Included in the Study, by Age
Age Category Minimum Number for Inclusion Maximum Number for Inclusion
50-59 years 800 subjects 1600 subjectsCCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 28Table 1. Intended Numbers of Subjects Included in the Study, b y Age
Age Category Minim um Number f or Inclusion Maximum Number for Inclusion
60-69 years 1600 subjects Not limited
70-79 years 1600 subjects Not limited
80 years 400 subjects Not limited
On monitoring the pooled primary  CDI event rates in different age groups, inclusion criteria 
subgroups, Charlson C omorbidity  Index61(CCI ) subgroups ,and other baseline factors, once 
the specified minimum numbers in each age group have been achieved, if a substantially  
higher pooled CDI event rate is observed in some subgroups, the intention may be to stop 
enrollment in lower -risk subgroups and complete enrollment with the higher- risk subgroups 
thereafter. This is mainly  to help to achieve the target ed total number of first primary  cases
in a timely  manner.
Subjects withdrawn from the study  after randomization will not be replaced, regardless of the 
reason for withdrawal.
3.2.Approximate Duration of the Study
As this study  is event -driven , the study  duration will be dependent on CDI event rate .The 
study  may  be terminated earlier for efficacy  or futility  as described in Section 9.5.
Given 
that this is an event -driven study , the end of t rial is defined as database lock as 
described in Section 13.
3.3.Approximate Duration of Subject Participation
Subjects will be followed f rom the time they sign the I CD until sufficient cases have been 
accrued to declare e fficacy  or futility . 
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study is 
considered approp riate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject
is suitable for this protocol.
Subject eligibility should be reviewed and documented by  an appropriate member of the 
invest igator’s stud y team before subjects are included in the study.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 294.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated ICD indicating that the subject has been 
informed of all pertinent aspects of the stud y.
2. Willing and able to comply with scheduled visits, vaccination plan, and other study  
procedures .
3. 50 Y earsor older at enrollment.
4.
Subjects with an increased risk of future contact with healthcare s ystems by virtue of :
At least 1inpatient hospitalization 2 nights’ duration in the previous 12 months; 
or
At least 2 emergency  room visits in the previous 12 months; or
At least 10 outpatient visits (primary  and/or secondary  care visits; defined as an 
in-person visit to the office/clinic of a prescribing healthcare pro vider for the 
purp
oses of the diagnosis, treatment ,or ongoing management of a medical 
condition, excluding pharmacy  and mental health visits) in the previous 
12months; or
Residence in a skilled nursing facility  (a residential institution that provides 
professional nursing care and rehabilitation services, usually following discharge 
from the hospital); or
Residence in a nursing home (a residential institution th at provides assistance with 
activities of daily  living); or
Inpatient hospitalization 2 nights’ duration scheduled  37 day s after 
randomization.
Orsubjects who have received s ystemic (ie,oral or injected )antibiotics for a 
minimum of 48 hours at any  time in the previous 12 weeks.
5.Ability  to be contacted by  telephone during study  participation .
6.
Negative urine pregnancy  test for female subject s of childbearing potential.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 30Female subjects of nonchildbearing potential must meet at least 1of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or phy siological 
cause; status may  be confirmed with a serum follicle -stimulating hormone (FSH) 
level confirming the postmenopausal state;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ; 
c.Have medically  confirmed ovarian failure. 
All other female subjects (including female subject s with tubal ligations) are 
considered to be of childbearing potential. 
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1. Investigat or site staff members directl y involved in the conduct of the study  and their 
family  members, site staff members otherwise supervised by  the i nvestigator, or 
subjects who are Pfizer employ ees, including their family  members, directly  involved 
in the conduct of the study .
2. Participation in other studies involving investigational drug(s) /vaccine(s) within
28daysprior to study  entry until Visit 5 (1 month after the third vaccination).
3. Previous administration of an investigational C difficile vaccine or C difficile mAb 
therap y.
4. Prior episode of CDI , confirmed by  either laboratory  test or diagnosis of 
pseudomem branous colitis at colonoscopy , at surgery ,or histopathologically . 
5. Receipt of blood products or immunoglobulins within 6 months before enrollment.
6.Subjects who may be unable to respond to vaccination because of : 
Metastatic malignancy ; or
End- stage rena l disease (glomerular filtration rate <15 mL /min/1.73 m2or on 
dialy sis); or
Any serious medical disorder that in the investigator’s opinion is likely  to be fatal 
within the next 12 months; or
Congenital or acquired immunodeficiency ; or
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 31Receipt of s ystemic corticosteroids ( 20 mg/day  of prednisone or equivalent) for 
14 day s within 28 day s of enrollment; or
Receipt of chronic s ystemic treatment with other known immunosuppressant 
medications, or radiotherapy, within 6 months of enrollment. 
7.Known infection with human immunodeficiency  virus (HIV).
8.Any bleeding disorder or anticoagulant therapy  that would contraindicate 
intramuscular injection .
9.Any contraindication to vaccination or vaccine components, including previous 
anaph ylactic reaction to any  vaccine or vaccine -related components.
10.Prior small -or large -bowel resection (does not include appendectomy ).
11.Any condition or treatment resulting in frequent diarrhea ( 3 loose stools per day  
more than once per month), as reported b y the subject.
12.Other acute or chr onic medical or ps ychiatric condition 
including recent (within the 
past y ear) or active suicidal ideation or behavior alor laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the subject inappropriate for entry  into this 
study .
13.Pregnant female subjects ; breastfeeding female subject s; fertile male subjects and 
female subject s of childbearing potential who are, in the opinion of the investigator, 
sexually  active and at risk for pregnancy  with their partner(s) and are unwi lling or 
unable to use 2highl y effective method sof contraception as outlined in this protocol 
from the signing of the informed consent until at least 28 day safter the last dose of 
investigational product.
4.3.Criteria for Temporarily Delaying Vaccine Administration
The following conditions are temporary  or self -limiting and a subject may be vaccinated 
once the condition(s) has/have resolved and no other exclusion criteria are met:
1.Current febrile illness (oral temperature of 100.4°F [38.0°C]) or other acute illness
(including diarrhea of 3 unformed stools within 24 hours) within 48 hours prior to 
investigatio nal product administration.
2.Subject has received nonadjuvanted seasonal or pandemic influenza vaccine within 
the previous 14 day s oradjuvanted seasonal influenza vaccine or an y noninfluenza 
nonstudy  vaccine within the previous 28 day s before investigation al product 
administration.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 323.If systemic corticosteroids have been administered short term (<14 day s) for 
treatment of an acute illness, investigational product administration should be delay ed 
until sy stemic corticosteroid use has been discontinued for at least 28 day s.Inhaled, 
intra-articular/intrabursal, or topical corticosteroids are permitted.
If a subject meets an y delay criteria for vaccination, all study procedures, including blood 
sample collection relating to that visit, should be delay ed until th e day  of vaccination.
4.4.Lifestyle Requirements
4.4.1. Contraception
All fertile male subjects and female subjects who are of childbearing potential who are, in the 
opinion of the investigator, sexually  active and at risk for pregnancy  with their partner(s) 
must agree to use 
2highly  effective method sof contraception consistentl y and correctly for 
the duration of the vaccination period and for at least 28 day safter the last dose of 
investigational product.  The investigator or his or her designee, in consul tation with the 
subject, will confirm that the subject has selected 2 appropriate method s of contraception for 
the individual subject and his or herpartner from the permitted list of contraception methods 
(see below) and will confirm that the subject has been instructed in its consistent and correct 
use.  A t time points indicated in the schedule of activities , the investigator or designee will 
inform the subject of the need to use 2 highly  effective methods of contraception consistently  
and correctl y and document the conversation and the subject’s affirmation in the subject’s 
chart (subject s
need to affirm their consistent and correct use of at least 2 of the selected 
methods of contraception) .  In addition, the investigator or designee will instruct the subject 
to call immediately  if 
1 or both of the selected contraception method s is discontinued or if 
pregnancy  is known or suspected in the subject or the partner .
Highl y effective methods of contraception are th ose that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie,perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulat ion (eg, oral, inserted, injected, implanted, transdermal) ,provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the entire 
study  and has been using that hormonal contraceptive for an adequate period of tim e to 
ensure effectiveness.  
2.Correctl y placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WI TH a separate spermicide product (ie,foam, gel, 
film, cream, or suppository ). For countries where spermicide is not available or condom 
plus spermicide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilization with absence of sperm in the postvasectomy  ejaculate .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 335.Bilateral tubal ligation/ bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accord ance with the device’s label).
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk assoc iated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
4.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical person nel for the 
study  is documented in the study  contact list located in thestudy  reference manual ( SRM ) .
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare p rofessional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga tor
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the established communication pathways between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the study .The contact 
number is not intended for use by the subject directly, and if a subject calls that number, he 
or she will be directed back to the investigat orsite.
5.INVESTIGATIONAL PRODUCTS
For the purp oses of this study , and per International Conference on Harmoni s ation ( ICH)
guidelines ,investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33) .
For this study , the investigational products are C difficile vaccine and placebo (saline). Since 
the appearance of these investigational products is not identical, the study  is 
observer -blinded .
5.1.Allocation to Investigational Product
Allocation of subjects to vaccine groups will proceed through the use of an i nteractive 
response technology  (IRT) system ( interactive Web- based response [ IWR]). Study personnel 
(either blinded or unblinded) will be required to enter or select information including but not 
limited to the user’s identification ( ID)and password, the protocol number ,andthe subject 
number. They will then be provided with a randomization number, vaccine assignment ,and 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 34dispensable unit (DU) or container number.  The IRT system will provide a confirmation 
report containing the subject number , randomization number ,and D U or container number 
assigned. The confirmation report must be retained by  the unblinded dispens er in the 
unblinded site files.
The study -specific I RT ref erence manual will provide the contact information and further 
details on the use of the IRT system .
5.2.Blinding of Site Personnel
In this observer -blinded study , the study  staff dispensing and administering the vaccine will 
be unblinded, but all other site study  personnel, including the principal investigator and the 
subject, will be blinded.
The principal investigator will assign the responsibility  of the unblinded 
dispenser /administrator to persons who will not participate in the evaluation of any  study  
subject.  More than 1 unblinded dispenser/administrator will be assigned per site. A member 
of the study  site staff or clinic pharmacy  should fulfill this role.  Contact between the 
unblinded dispenser and study  subjects should be kept to a minimum.  The in vestigator, stud y 
coordinator, and an y site staff other than the unblinded dispenser/administrator must not be 
allowed to know the investigational product assigned to an y study subject and must not be 
allowed to see the investigational product container co ntents.
5.3.Blinding of the Sponsor
Those study  team members who are involved in ensuring that protocol requirements for 
investigational product handling, allocation, and administration are fulfilled at the site 
(eg,study  manager; clinical research associate s [CRAs]) will be unblinded for the duration of 
the study . All other study  team members and all l aboratory  personnel performing the stool 
and serology  assay s will remain blinded to vaccine assigned/received throughout the study .  
5.4.Breaking the Blind 
The study  will be subject and investigator blinded .
At the initiation of the study , the investigator site will be instructed on the method for 
breaking the blind.  The method will be an electronic process.  Blinding codes should be 
broken only in exceptional circumstances when knowledge of the actual vaccine assignment
is absolutely  essential for further management of the subject. Investigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary . When 
the blinding code is broken, the reason must be fully  documented and entered on the case 
report form (CRF) .
5.5. Subject Compliance
All doses of investigational product will be administered by  the appropriately  designated 
study  staff at the investigator s ite.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 355.6.Vaccine Supplies
5.6.1. Formulation and Packaging
5.6.1.1. Clostridium difficile Vaccine
The investigational C difficile vaccine is toxoid based. C difficile toxin A and toxin B are 
inactivated b y a combination of genetic mutations and chemical treatments.  The vacci ne is 
provided as a sterile ly ophilized powder in a dosage strength of 200µg/dose (total for 
toxoids A and B).  The vaccine will be reconstituted with AlOH diluent immediately  before 
use as instructed in the investigational product (IP) manual.   The AlOH diluent is supplied as 
a 1-mg aluminum/mL  (as AlOH ) liquid suspension.
Blinded, sealed cartons will contain 1 single -use vial of C difficile vaccine lyophilized 
powder for reconstitution and 1 single -dose s yringe of AlOH diluent.  The total volume of 
resuspended vaccine to be injected is 0.5 mL per dose.
The investigational products will be provided by  the sponsor to each study  site.  
Investigational product and diluent will be packed and labeled b y Pfizer or its designee as 
investigational product in accordance with current guidelines and applicable local and legal 
regulatory  requirements.  For detailed information on the antigenic components of the 
investigational pr oduct, please refer to the IB.
5.6.1.2. Placebo
The placebo will consist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection, in a 0.5 -mL dose) and will be provided by  the sponsor to each study  site.
The placebo will be packaged within cartons labeled by  Pfizer or its designee in accordan ce 
with current guidelines and applicable local and legal regulatory  requirements.  Blinded, 
sealed cartons will contain 1 single
-dose sy ringe of placebo.  Refer to the IP manual for 
details regarding the preparation and dispensing of placebo.
5.6.2. Preparation and Dispensing
See the IP manual for instructions on how to prepare the investigational product for 
administration.  I nvestigational product should be prepared and dispensed by  an 
appropriatel y qualified and experienced unblinded member of the study  staff .
5.6.3. Administration
All injections will be administered in the upper deltoid muscle, preferabl y of the 
nondominant arm, by  the unblinded administrator.  
Subjects will receive 1 dose of C difficile vaccine/placebo at Visits 1 (Month 0), 2 (Month 1), 
and 4 (Mon th6). 
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance with local guidelines for standard 
immunization practices.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 36Administration of investigational products should be performed b y an appropriately 
qualified, Good Clinical Practice ( GCP)-trained, and vaccine-experienced member of the 
study  staff (eg, ph ysician, nurse, ph ysician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as allowed b y local, state, and institutional guidance. 
Investigational product administration details will be recorded on the CRF.
5.7. Investigational Product Storage
The investi gator or an approved representative, eg , pharmacist, will ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements .
Investigatio nal product sshould be stored in their original container sand in accordance with 
the label s.
See the IP manual for storage conditions of the product once reconstituted.
Any storage conditions stated in the SRSD willbe superseded b y the storage conditions 
stated on the product label.
The investigational vaccine, AlOH diluent, and placebo will be shipped at +2 C to +8C to 
each stud y site after required regulatory and legal documents have been received b y the 
sponsor. Upon receipt at the 
study  site, the products should be immediately  transferred to a 
+2C to +8C temperature -monitored refrigerator for storage.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum tempera tures for all site storage locations (as 
applicable, including frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous
-monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and t o provide the site with the capability  to store or view the minimum/maximum 
temperature for all nonworking day s upon return to normal operations.  The operation of the 
temperature -
monitoring device and storage unit (for example, refrigerator), as applicabl e, 
should be regularl y inspected to ensure they are maintained in working order.
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery . The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer .
Once an excursion is identified, the investigational product must be quar antined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 37considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine han dling operations where 
the products are briefl y out of thetemperature range described in the labeling are not 
considered excursions.
5.8. Investigational Product Accountability
The investiga torsite must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.   All investigational products will be 
accounted for using a drug accountabilit y form/record.
5.8.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of unused investigational 
product (eg, at the site).  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer, and all destruction must be adequatel y documented.
5.9. Concomitant Medication(s)
5.9.1. Recording Concomitant Vaccinations and Medications
The following concomitant medications and vaccinations will be recorded in the CRF:
All vaccinations received from 28 day sprior to study  enrollment until Visit 5 (Month 7 
[1 month after the third vaccination ]).
At the time of a suspected CDI case, start date, name of medication, dose, unit, route, and 
frequency  will be recorded for the following:
Antibiotic use with in the 12 weeks prior tothe onset of the suspected CDI  case .
Antibiotic use for the treatment of the suspected CDI  case .
Known immunosuppressant medication, or radiotherap y use, within the 6 months 
prior to the onset of the suspected CDI case.
Systemic corticosteroid use within the 28 day s prior to the onset of the suspected CDI 
case.
Proton -pump inh ibitor use within the 12 weeks prior to the onset of the suspected 
CDI case .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 385.9.2. Prohi bited Concomitant Vaccinations and Medications
Receipt of the following prohibited vaccines and medications during the time periods listed 
below may  exclude a subject from the per -protocol analy sis, and may  require vaccinations to 
be discontinued in that s ubject ; however, it is anticipated that the subject would not be 
withdrawn from the study (see Section 6.2).
Unless considered medically  necessary , no vaccines other than investigational product should 
be administered within 28 day s before and 28 days after each study  vaccination 
(administered at 
Visit s 1, 2, and 4 ).One exception to this is that nonadjuvanted seasonal 
influenza vaccine and pandemic influenza vaccine can be given at least 14 day s after, or at 
least 14 day s prior to, the administration of investigational product.
Receipt of chronic s ystemic treatment with other known immunosuppressant medications, or 
radiotherap y, within 6 months before enrollment through conclusion of the study .
Receipt of s ystemic corticosteroids ( 20 mg/day  of prednisone or equivalent) for 14 day s is 
prohibited from 28days prior to enrollment to Visit 5 (Month 7). 
Receipt of blood products or immunoglobulins within 6 months before enrollment through 
conclusion of the study .
Receipt of an y other (nonstudy ) investigational C difficile vaccine o
r C difficile mAb therap y
at an y time prior to or during stud y participation is prohibited .
Prophy lactic antipy retics and other pain medication to prevent symptoms associated with 
investigational product administration are not permitted.  However, if a sub ject is taking a 
medication for another condition, even if it may  have antipy retic or pain -relieving properties, 
it should not be withheld prior to study  vaccination.
5.9.3. Permitted Concomitant Medications
The use of antip yretics and other pain medication to treatsymptoms associated with 
investigational product administration or ongoing conditions is permitted.
Medication other than that described as prohibited in Section 5.9.2 required for treatment of 
preexisting stable conditions is permitted.
Inhaled, topical, or localized injections of corticosteroids (eg, intra -articular or intrabursal 
administration) are permitted.
6.STUDY PROCEDURES
6.1.Study Period
Throughout the study period, if a subject has had no study -related activity  for at most 
1month ,thesubject will receive an electronic reminder to confirm that he or she is still 
active in the study  and to remind the subject to record when he or she experience san 
unformed stool and to collect a sample when required (see Section 6.1.9 and Section 6.4).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 39If the subject is unresponsive to the electronic reminder, the site staff should contact him or 
herby telephone. Site staff will be able to record that a subject is still active in the electronic 
diary  (e-diary )vendor portal. In addition, all subject s will receive a reminder every  2 weeks 
to collect a stool sample should a diarrheal episode occur (3 or more diarrheal episodes ,
Bristol ty pe 5-7, within 24 hours).
Deaths will be recorded for the entire stud y duration, as follows :
a.Occurring within 30 day s of a diarrheal episode: death should be recorded on the relevant 
CRF page related to the diarrheal episode (see Section 6.1.9). In addition, dependent on 
the timing within the study , bor c below should also be followed.
b. Occurring between provision of informed consent and Visit 6: the underly ing cause 
should be reported as a nSAE (see Section 8.2.3) with death as the outcome.
c.Occurring after Visit 
6and before the end of the study : the date and cause of death should 
be recorded on the relevant CRF page. For reporting requirements outside of the active 
collection period, see Section 8.1.4.1.
6.1.1. Visit 1: 
Month 0 –Vaccination 1
It is anticipated that the procedures below will be conducted in a stepwise manner ; ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccin ation.
Obtain written informed consent prior to performing an y protocol required procedures.
Record the subject’s demograph y (including date of birth, sex, race, and ethnicity). 
Conduct a clinical assessment, including review of medical history , to verify  that a ll 
inclusion criteria, none of the exclusion criteria, and none of the temporary delay  criteria 
are met ( Section 4). Record medica l history  of significance, including the presence of 
chronic medical conditions. If the clinical assessment indicates that a ph ysical 
examination is necessary to comprehensivel y evaluate the subject, perform a physical 
examination and record the findings.
Record nonstud y vaccines as described in Section 5.9.1.
Measure and record the subject’s weight andheight
.
Measure and record the subject’s oral temperature.
For female subjects of childbearing potential, perform a urine pregnancy  test and ensure 
the result is negative prior to vaccination (Section 7.5).
Discuss contraceptive use .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 40Ensure that all inclusion criteria, none of the exclusion criteria, and none of the temporary  
delay  criteria are met ( Section 4).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s randomization number and investigational prod uct blinded carton 
number. 
Collect a blood sample of approximately  20 mL for immunogenicit y testing ( Section 7.3).
Unblinded sitestaff will prepare and administer investigational product. Investigational 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recorded.  Refer to 
the IP manual under separate cover for further instruction on this process.
The unblinded vaccine dispenser/ administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute reactions. Any AEs noted during the observation 
period should be recorded in the CRF.
Record and report AEs and SAEs (relative to the time of vaccination) as described in
Section 8 and the schedule of activities .
Review the stool sample collection and shipping instructions with the subject and ensure 
the subject acknowledges understanding, including the requirement to contact the courier 
for sample collection (s ee Section 6.3).
Issue the stool colle ction kit and shipping box and pr ovide instructions on their use 
(
see Section 6.3).
Explain the communication technologies available for the stud y(which also allow for the 
completion of the e -diary) , and assist the subject in downloading the stud y application 
(app) onto the subject’s own de vice or issue a provisioned device if required
(
seeSection 6.4).
Issue a measuring device for measurement of local reactions, and a digital thermometer 
for recording dail y temperatures .
Provide instructions on their use and recording .
Explain the e -diary  platform to collect vaccine reactogenicit y data and provide 
instructions on its completion. Ask the subject to complete the e -diary  from Day 1 to 
Day 7, with Day 1 being the day  of vaccination.
Ask the subject to contact the site staff or investigato r immediately if he or she 
experiences 3 or more unformed stools (Bristol stool chart ty pes 5 -7) in any 24 -hour 
period.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 41Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.2. Visit 2: Month 1 –Vaccination 2 (28 to 42 Days After Visit 1)
It is anticipated that the procedures below will be conducted in a stepwise manner ;
ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
Review the subject’s e -diary  data and follow up on any ongoing local reactions or 
systemic events.
Ensure that the subject continues to be elig ible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
Discuss with the subject to deter mine whether an y major protocol violations have 
occurred, as described in Section 6.2.1, and record in source documents .
Based on clinical evaluation, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8 and the schedule 
of activities .  Review AEs that were ongoing from the previous visit and record their stop 
dates or confirm if they  are still continuing .
Record nonstud y vaccines as described in Section 5.9.1 .
Measure and rec ord the subject’s oral temperature.
For female subjects of childbearing potential, perform a urine pregnancy  test and ensure 
the result is negative prior to vaccination (Section 7.5).
Discuss contraceptive use .
Ensure that none of the temporary  delay  criteria are met ( Section 4.3).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s investigational product blinded carton number. 
Unblinded site staff will prepare and administer investigational product. Investigational 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recorded.  Refer to
the IP manual under separate cover for further instruction on this process.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 42The unblinded vaccine dispenser/ administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes afte r investigational 
product administration for an y acute reactions.  Any AEs noted during the observation 
period should be recorded in the CRF.
Record and report AEs and SAEs (relative to the time of vaccination) as described in 
Section 8 and the schedule of activities.
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(seeSection 6.3). 
Ensure the subject has an available stool collection kit and shipping box and provide 
instructions on their use, as required (
see Section 6.3).
Ensure the subject is comfortable with his or her chosen communication technology
(
see Section 6.4).
Ensure the subject has an available measuring device for measurement of local reactions, 
and a digital thermometer for recording dail y temperatures. If required, p rovide 
instructions on their use.
Confirm that the subject understands the reactogenicity  reporting requirements. Remind 
the subject to complete the e
-diary  from Day 1 to Day 7, with Day 1 being the day  of 
vaccination.  
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.3. Visit 3: Month 2 (28 to 42 Days After Visit 2)
Review the subject’s e -diary  data and follow up on any ongoing local reactions or 
systemic events.
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 43Discuss with the subject to determine whether any major protocol violations have 
occurred, as described in Section 6.2.1 ,and record in source documents.
Based on clinical evaluation, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8 and the schedule 
of activities .  Review AEs that were ongoing from the previous visit and record their stop 
dates or confirm if they  are still continuing. 
Record nonstud y vaccines as described in Section 5.9.1.
Collect a blood sample of approximately  20 mL for immunogenicit y testing ( Section 7.3).
Discuss contraceptive use.
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(
seeSection 6.3). 
Ensure the subject has an available stool collection kit and shipping box and provide 
instructions on their use, as required (see Section 6.3).
Ensure the subject is comfortable with his or her chosen communication technology
(
seeSection 6.4).
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.4. Visit 4: Month 6 –Vaccination 3 (1 40to 16 8Days After Visit 2)
It is anticipated that the procedures below will be conducted in a stepwise manner ;
ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.
Review the subjec t’s e-diary  data and follow up on any ongoing local reactions or 
systemic events .
Ensure that the subject continues to be eligible for the study  and does not meet any  of the 
withdrawal criteria as described in Section 6.2.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 44Discuss with the subject to determine whether an y major protocol violations have 
occurred, as described in Section 6.2.1 ,and record in source documents.
Based on clinical evaluation, determine whether any  AEs or SAEs have occurred since 
the last study  visit.  Record and report findings as described in Section 8and the schedule 
of activities .  Review AEs that were ongoing from the previous visit and record their stop 
dates or confirm if they  are still continuing. 
Record nonstud y vaccines and as described in Section 5.9.1.
Measure and record the subject’s oral temperature.
For female subjects of childbearing potential, perform a urine pregnancy  test and ensure 
the result is negative prior to vaccination (Section 7.5).
Discuss contraceptive use.
Ensure that none of the temporary  delay  criteria are met ( Section 4.3).
An appropriate site staff member (may  be blinded or unblinded) will use the I RT s ystem 
to obtain the subject’s investigational product blinded carton numb er. 
Unblinded site staff will prepare and administer investigational product. Investigational 
product will be administered b y intramuscular injection into the upper deltoid muscle, 
preferabl y of the nondominant arm. The time of vaccination will be recor ded.  Refer to 
the IP manual under separate cover for further instruction on this process.
The unblinded vaccine dispenser/ administrator updates the investigational product 
accountability  records.
Blinded study  staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute reactions.  Any AEs noted during the observation 
period should be recorded in the CRF .
Record and report AEs and SAEs (relative to the time of vaccination) as described in 
Section 8 and the schedule of activities.
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(seeSection 6.3). 
Ensure the subjec t has an available stool collection kit and shipping box and provide 
instructions on their use, as required (
see Section 6.3).
Ensure the subject has an available measuring device for measurement of local reactions, 
and a digital thermometer for recording dail y temperatures. If required, provide 
instructions on their use.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 45Ensure the subject is comfortable with his or her chosen communication technology
(seeSection 6.4).
Remind the subject to complete the e -diary from Day 1 to Day 7, with Day 1being the 
day of vaccination.
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.5. Visit 5: Month 7 (28 to 42 Days After Visit 4)
Review the subject’s e -diary  data and follow up on any ongoing local reactions or 
systemic events.
Discuss with the subject to determine whether an y major protocol violations have 
occurred, as described in Section 6.2.1, and record in source documents.
Based on clinical evaluation, determine whether any
 AEs or SAEs have occurred sinc e 
the last study  visit.  Record and report findings as described in Section 8and the schedule 
of activities .  Review AEs that were ongoing from the previous visit and record their stop 
dates or confirm if they  are still continuing. 
Record nonstud y vaccines and as described in Section 5.9.1.
Collect a blood sample of approximately  20 mL for immunogenicit y testing ( Section 7.3).
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(
see Section 6.3). 
Ensure the subject has an available stool collection kit and shipping box and provide 
instructions on their use, as required (
see Section 6.3).
Ensure the subject is comfortable with his or her chosen communication technology
(
seeSection 6.4).
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 46Ask the subject to contact the site staff or investigator immediately  if any  significant 
illness or hospitalization occurs.
Schedule an appointment for the subject to return for the next study  visit.
Complete the source documents.
Complete the CRF.
6.1.6. Visit 6: Month 12 (165 to 195 Days After Visit 4)
Visit 6 is intended to be conducted b y telephone but, if desired, may be conducted in 
person.
Discuss with the subject to determine whether an y major protocol violations have 
occurred, as described in Section 6.2.1 ,and record in source documents.
Following the provided script (found in the SRM) , contact the subject b y telephone to
determine whether an y SAEs have occurred since the last study visit.  Record and report 
findings as described in Section 8 and th e schedule of activities .  Review AEs that were 
ongoing from the previous visit and record their stop dates or confirm if they  are still 
continuing.
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(see Section 6.3). 
Ensure the subject has an available stool collection kit and shipping box and provide 
instructions on their use, as required (
see Section 6.3).
Ensure the subject is comfortable with his or her chosen communication technology  
(
seeSection 6.4).
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
Complete the source documents.
Complete the CRF.
6.1.7. Annual Retention Visits ( Every 280 to 392 D ays A fter Visit 5)
As the study  is event driven, it is imperative that subjects remain engaged and comfortable 
with the study  requirements. As the study  duration increases, in
-person retention visits will 
be used to facilitate this intent. 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 47An annual retention visit should be arranged at the earliest opportunity  for subjects already  
enrolled in the study , following approval of Amendment 3, and then every  280 to 392 day s 
thereafter.
At the time of a retention visit:
At the first annual retention visit or potential CDI  visit ,whichever comes first following 
approval of Amendment 3, obtain written informed consent to the amend ments in the
protocol .  
Discuss with the subject to determine whether an y major protocol vio lations have 
occurred, as described in Section 6.2.1 ,and record in source documents.
Confirm that the subject understands the stool sample collection and shipping 
requirements, including the mechanism to contact the courier for sample collection 
(see Section 6.3). 
Ensure the subject has an available stool collection kit and shipping box and provide 
instructions on their use, as required (
see Section 6.3).
Ensure the subject is comfortable with his or her chosen communication technology  
(
seeSection 6.4).
Ask the subject to contact the site staff or investigator immediately  if he or she 
experiences 3 or more unformed stools in any  24
-hour period.
Complete the source documents.
Complete th e CRF.
6.1.8. Visit 7: End of Study
Discuss with the subject to determine whether an y major protocol violations have 
occurred, as described in Section 6.2.1 ,and record in source documents.
Telephone the subject and advise him or her that the study  has ended.
Instruct the subject how to return the study  materials, including a provisioned device, if 
applicable.
6.1.9. At the Time of a Potential CDI Case ( Follow -up Related to E achDiarrheal 
Episode )
When the subject experiences 3 or more unformed stools (Bristol stool chart ty pes 5 -7) in a 
24-hour period, having collected the third or subsequent stool for provision to the central 
laboratory ,he or she is instructed to contact the site. This contact will trigger the following 
procedures that will include at least 1in-person visit (eg , at the subject’s home, at the study  
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 48site, or in a medicall y attended setting) and may necessitate additional telephone follow -up 
with the subject . Information will be recorded in the CRF:
Collect a blood sample of approximately 20 mL (a minimum of 10 mL  and up to 20 mL)
for immunogenicity  testing ( Section 7.3). Optimally , this should be collected within 
48hours of the third unformed stool (Bristol stool chart ty pes 5 -
7).
Record an y AEs occurring up to 48 hours after the blood draw.
Collect the following information , including but not limited to:
oStart and stop dates of the diarrhea l episode .
oTotal number of unformed stools (Bristol stool chart ty pes 5 -7).
oType and result of any  microbiological test performed locally  for detection of 
Cdifficile and its toxins.
oConcomitant medications received (see Section 5.9.1 ). 
oNumber and nature of any  non–protocol -related med ically attended visits up to 
1month after the resolution of the episode.
oAny new diagnosis 
(since enrollment) of metastatic malignancy , end -stage renal 
disease (glomerular filtration rate <15 mL/min/1.73 m2or on dialy sis), or infection 
with HIV.
oIf hospi talized: serum creatinine, serum albumin, total leu kocyte count, results of 
microbiological tests performed for detection of stool pathogens other than C difficile , 
nonmicrobiological diagnostic procedures performed (eg, c omputed tomography
scan, endoscop y), length of stay , number of day s spent in intensive care, requirement 
for mechanical ventilation, presence of renal failure, requirement for parenteral 
nutrition, surgical procedures performed .
Discuss with the subject to determine whether any major protocol violations have 
occurred, as described in Section 6.2.1, and record in source documents.
6.1.10.
Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction
If a Grade 3 local reaction ( Section 7.2.1.2), s ystemic event ( Section 7.2.1.3 ), or fever 
(Section 7.2.1.4 ) is reported in the e- diary ,a telephone contact should occur to ascertain 
further details and determine whether a site visit is clinically  indicated.
If a suspected Grade 4 local reaction ( Section 7.2.1.2 ), systemic event ( Section 7.2.1.3), or 
fever (Section 7.2.1.4) is reported ,a telephone contact or site visit should occur to confirm 
whether the event meets the criteria for Grade 4.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 496.2.Subject Withdrawal
Subject eligibility  must be confirmed prior to each vaccination in order to continue in the 
study . 
If a subject no longer meets the eligibility  criteria during the vaccination period of the study , 
discontinuation of further vaccinations should be considered, but the subject may remain in 
the study  and be followed up per the schedule o f activities. If a subject no longer meets the 
eligibility  criteria after the vaccination period of the study , and is willing to remain in the 
study , the subject may do so and will be followed up per the schedule of activities .
Subjects may withdraw from the study  at any  time at their own request, or they may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also the 
Withdrawal From the Study  Due to Adverse Events section) or behavioral reasons, or the 
inability  of the subject to comply  with the protocol -require d schedule of study  visits or 
procedures at a given study  site.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  
All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the subject return for a final vis it, if applicable, 
and follow up with the subject regarding an y unresolved AEs .
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data sho uld be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
6.2.1. Major Protocol Violations
In order to define the per -protocol anal ysis populations ( Section 9.2), it is important to 
determine which subjects have experienced what may  constitute a major protocol violation at 
any time during the study. At each study  contact after Visit 1, 
site staff s hould record if any  
of the following has occurred:
Subject met e xclusion criteria 1, 2, 6, 7, 8, 9, 12, and 13(Section 4.2).
Subject in whom vaccination was not appropriately delay ed following receipt of 
short -term (<14 day s) systemic cor ticosteroids for treatment of an acute illness
(Section 4.3).
Subject r eceivedchronic sy stemic treatment with other known immunosuppressant 
medications, or radiotherapy , through the 
conclusion of the study (Section 5.9.2).
Subject r eceivedsystemic corticosteroids ( 20 mg/day  of prednisone or equivalent) for 
14 day s through Visit 5 (Month 7) (Section 5.9.2 ). 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 50Receipt of blood products or immunoglobulins through the conclusion of the study
(Section 5.9.2). 
6.3.Stool Sample 
Collection
Stool samples (the third or subsequent unformed stool [Bristol stool chart types 5 -7] in a 
24-hour period) will be collected in either the subject’s home or amedical setting 
(eg, hospital, nursing home).  Site staff will review the sample coll ection and shipping 
instruction swith each subject and ensure that 
thesubject understands the appropriate 
procedures for collecting and properl y packaging stool samples.  All subjects will be 
provided with a stool sample collection kit and shipping box atVisit 1and with replacement 
kits as needed throughout the study . For some subjects , assistance may  be provided for stool 
collection from the subject’s own caregiver, healthcare assistants, community nurses, site 
staff, or equivalent , if required . 
The process for stool collection and transport to the processing center is detailed in the SRM.
6.4.Subject Communication and Use of Technology
In a study  of this duration that is event -driven, it is vital to ensure that communication 
between the stud y site and the subject is maintained to ensure that endpoint events are not 
missed. This study  will employ  various methods, tailored to the individual subject, to ensure 
that communication is maintained and stud y information can be transmitted securel y. Using 
appropr iatetechnology ,a communication pathway between the subject, the site , and the stool 
sample courier will be established. Subjects may  be able to utilize their own devices to 
access this technology , or use a device provided by  the sponsor. Traditional me thods of 
telephone communication will also be available. The technology  solution may facilitate :
Contact to the courier for stool sample shipping .
Contact to the investigator.
The subject to record individual unformed stools, and alert t he subject of a third 
unformed stool in 24 hours (a diarrheal event) .
An alert in the event a subject is hospitalized.
Access to stud y information, including stool collection instructions.
Visit reminders.
Reminders to ensure stool sample collection and shipping for diarr heal episodes.
Messages of th
anks and encouragement from the study  team.
A platform for recording local reactions and s ystemic events (e-diary ).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 517.ASSESSMENTS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y toensure the 
safet y and well -being of the subject. When a protocol -required test cannot be performed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
7.1.Efficacy Assessments
Any time during the study  period that a subject experiences passage of 3 or more unformed 
stools (Bristol stool chart ty pes 5 -7) within 24 hours, the subject will be asked to collect the 
third or subsequent stool for provision to the central laboratory .  The subject will be provided 
with a sample collection kit and be instructed on how to package the sample.  The sample 
will be shipped to a processing laborato ry.  The processing laboratory  will prepare aliquots of 
the stool for later anal ysis at the central laboratory .
7.1.1. Central 
Laboratory Testing for Clostridium difficile
All diarrheal specimens submitted to the central laboratory  will initially  be tested by PCR to 
detect C difficile that harbors TcdB .PCR- positive samples will be tested in a second step for
presence of free toxins ( Figure 1).
Figure 1.Two - Step Testing Algorithm for Determination of Clostridium difficile
Infection Case Definition
Abbreviations: CDI = Clostridium difficile infection; PCR = polymerase chain reaction.

PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 527.1.1.1. Detection of Toxigenic Clostridium difficile byPCR
A commerciall y available, Food and Drug Administration ( FDA )-approved and Conformité 
Européenne (CE) -marked assay  will be used for the rapid detection of toxigenic C difficile
and for the presumptive identification of 027/NAP1/BI strains of toxigenic C
difficile from 
the subjects’ 
stool samples .  The test is designed to detect thetoxinBgene (tcdB) sequences 
associated with toxin -producing C difficile . PCR results and the corresponding action taken 
for the tested samples areoutlined in Table 2.
Table 2. Cepheid Xpert C.difficile /EpiResults
Result Action
Toxigenic C difficile negative; 027 presumptive 
negativeSample is reported as C difficile negative.  No further 
testing
Toxigenic C difficile positive; 027 presumptive 
negativeTest sample forthe presence of free toxins
Toxigenic C difficile positive; 027 presumptive 
positiveTest sample forthe presence of free toxins
Invalid Sample is retested
Note: The Cepheid Xpert C. difficile/Epi is a test for detection and differentiation of Clostridium difficile and 
the epidemic 027 strain .
7.1.1.2. Detection of Free Toxins in the Stool Sample 
The assay  used to detect presence of free toxins will be described in the laboratory  manual
maintained by
 the sponsor.
7.1.2. Diagnosis of Pseudomembranous Colitis
The primary  CDI case definition can also be met via a definitive demonstration of 
pseudomembranous colitis and corresponding stool sample that is positive for the toxin B 
gene ( byPCR) as measured in the central laboratory . Thediagnosis of pseudomembranous 
colitis could be made during colonoscop y or surgery or byhistopathological examination.
7.2.Safety Assessm ents
Safety  parameters will be assessed as described in the Schedule o f Activities , Section 6, 
Section 8, and below. 
A clinical assessment, including medica l history , will be performed on all subjects at Visit 1 
to establish a baseline. Significant medical history  and observations from any physical 
examination , if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.
Acute reactions within the first 30 minutes after investigational product administration will 
be assessed and documented in the AE CRF.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 53The safet y parameters also include e -diary  reports of local reactions and s ystemic events that 
occur in the 7 days after investigational product administration.  These prospectivel y 
collected occurrences of local reactions and systemic events are graded as described in
Section 7.2.1.
7.2.1. Electronic Diary
Subjects will be required to use an e-diary , based on 
appropriate technology, and will be 
asked to monitor and record local reactions and systemic events for 7days following 
vaccination . The e -diary allows recording of these assessments onl y within a fixed time 
window, thus providing the accurate representa tion of the subject’s experience at that time.  
Data on local reactions and systemic events reported on the e -diary  will be tr ansferred 
electronically  to a third- party  vendor, where they  will be available for review by  investigators 
and the Pfizer clinicians at all times via an Internet -based portal. E
-diary  data review is 
ongoing during subject e- diary  data -entry  periods ( 7days after each vaccination) via an 
Internet -based portal.
At intervals agreed to b y the vendor and Pfizer, these data will be transferred electronicall y 
into Pfizer's database for anal ysis and reporting.  These data do not need to be reported by  the 
investigator in the CRF as AEs.
Investigators (or designee) will be required to review the e -diary  data online at frequent 
intervals as part of the ongoing safet y review.
The investigator or designee must contact the subject in order to obtain stop dates for an y 
ongoing local reactions or sy stemic events on the last day  that the e -diary  was completed.  
The stop dates should be documented in the source documents and the information entered in 
the CRF.
7.2.1.1. Grading Scales
The grading scales used in this study  to assess local reactions and systemic events as 
descr ibed below are derived from the FDA Center for Biologics Evaluation and Research 
(CBER) guidelines on toxicity  grading scales for healthy  adult volunteers enrolled in 
preventive vaccine clinical trials .62
7.2.1.2. Local Reactions
During the e -diary  reporting period, subjects will be asked to assess redness, swelling, and 
pain at the injection site and to record the s ymptoms in the e -diary .  If a local reaction
persists beyond the end of the e -diary  period following vaccination, the subject will be 
requested to report that information.  The investigator will enter this additional information in 
the CRF.
Redness and swelling will be measured and recorded in measu ring device units (range: 1 to 
21) and then categorized during anal ysis as absent, mild, moderate, or severe based on the 
grading scale in Table 3.  M easuring device units can be converted to centimeters according 
to the following formula: 1 measuring device unit = 0.5 cm.  
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 54Pain at the vaccine injection site will be assessed by  the subject as absent, mild, moderate, or 
severe according the grading scal e in Table 3.
If a Grade 3 local reaction is reported in the e
-diary ,a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. Only an 
investigator or medicall y qualified person is able to classify a subject’s local reaction as 
Grade 4. If a subject experiences a confirmed Grade 4 local reac tion, the investigator must
immediately  notify  the sponsor and, if it is determined to be related to the administration of 
the investigational product, further vaccinations will b e discontinued in that subject.
Table 3. Local Reacti on Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Pain Does not interfere 
with activityInterferes with 
activityPrevents daily activity Emergency room visit 
or hospitalization for 
severe pain
Erythem a/
Redness2.5cm to 5.0 cm (5 to 
10measuring device 
units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(21measuring 
device units)Necrosis or 
exfoliative dermatitis
Induration/
Swelling2.5cm to 5.0 cm (5 to
10 measuring device 
units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10cm 
(21measuring 
device units)Necrosis
7.2.1.3. Systemic Events
During the e -diary  reporting period, subjects will be asked to assess vomiting, headache, 
fatigue, new or worse ning muscle pain, and new or worsening joint pain and to record the 
symptoms in the e -diary .  The sy mptoms will be assessed by  the subject as absent, mild, 
moderate, or severe according to the grading scale in Table 4.
If a Grade 3 s ystemic event is reported in the e
-diary ,a telephone contact should occur to 
ascertain further details and determine whether a site visit is clinically  indicated. Only an 
investigator or medically qualified person is able to cla ssify  a subject’s s ystemic event as 
Grade 4. If a subject experiences a confirmed Grade 4 systemic event , the investigator must
immediately  notify  the sponsor and, if it is determined to be related to the administration of 
the investigational product, further vaccinations will b e discontinued in that subject.
Table 4. Systemic Event Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threaten ing 
(Grade 4)
Vom iting 1-2 times in 
24hours>2 times in 
24hoursRequires IV 
hydrationEmergency room visit or 
hospitalization for 
hypotensive shock
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 55Table 4. Systemic Event Grading Scale
Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threaten ing 
(Grade 4)
Headache No interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityEmergency room visit or 
hospitalization for severe 
headache
Fatigue/ 
TirednessNo interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityEmergency room visit or 
hospitalization for severe 
fatigue
New or 
worsening 
muscle painNo interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityEmergency room visit or 
hospitalization for severe 
new or w orsening muscle 
pain
New or 
worsening 
joint painNo interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityEmergency room visit or 
hospitalization for severe 
new or w orsening joint pain
Abbreviation: IV = intravenous.
7.2.1.4. Fever
In order to record information on fever, a digital thermometer will be given to subjects with 
instructions on how to measure oral temperature at home.  Temperature will be collected in 
the e -diary  in the evening daily  during the e -diary  reporting period.  It will also be collected 
at an y time during the e -diary  data collection periods when fever is suspected.  Fever is 
defined as an oral temperature of 38.0C (100.4 F).  The highest temperature for each day  
will be recorded in the e -diary .Temperature will be measured and recorded to 1 decimal 
place and t hen categorized during anal ysis according to the scale shown in Table 5.
If a Grade 3 fever is reported in the e
-diary ,a telephone contact should occur to ascertain 
further details and determine whether a site visit is clinically  indicated. Only  an investigator 
or medicall y qualified person is able to cla ssify  a subject’s fever as Grade 4. If a subject 
experiences a confirmed Grade 4 fever , the investigator must immediatel y notify  the sponsor 
and, if it is determined to be related to the administration of the investigational product, 
further vaccinations will be discontinued in that subject.
Table 5. Scale for Fever
Mild (Grade 1) 38.0-38.4C (100.4 -101.1 F)
Moderate (Grade 2) 38.5-38.9C (101.2 -102.0 F)
Severe (Grade 3) 39.0-40.0C (102.1 -104.0 F)
Potentially Life Threatening ( Grade 4 ) >40.0 C (>104.0 F)
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 56 
 
 
 
 
 
 
 
7.4. Other Assessments
At the time of a diarrheal episode, the site will complete a questionnaire with the subject to 
collect information on severity, duration, treatment of, and healthcare utilization associated with the episode.
7.5. Pregnancy Testing
For female subjects of childbearing potential, a urine pregnancy test, with sensitivity of at 
least 25 mIU/mL, will be performed immediately before administration of each vaccine dose.  A negative pregnancy test result is required before the subject may receive the investigational product. Pregnancy tests may also be repeated if requested by institutional review boards (IRBs)/ethics committees (ECs) or if required by local regulations. In the case of a positive confirmed pregnancy, the subject will be withdrawn from administration of investigational product but may remain in the study.
Urine pregnancy tests must be sensitive to at least 25 mIU/mL and will be conducted with the 
test kit provided by the sponsor in accordance with instructions provided in its package insert.  Subjects who have missed a menstrual period or who show an indeterminate or positive result on the qualitative point-of-service urine test may not further progress in the study until pregnancy is ruled out using further diagnostic testing (eg, a negative quantitative serum pregnancy test conducted at a certified laboratory).CCI
CCI
CCI
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 57 
 
 
 
 
 
 
  
 
8. ADVERSE EVENT REPORTING
8.1. RequirementsThe table below summarizes the requirements for recording safety events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form to Pfizer Safety.  These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious AEs; and (3) exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the investigational product under study during 
pregnancy or breastfeeding, and 
occupational exposureAll (regardless of whether associated 
with an AE), except occupational 
exposureExposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure (regardless of 
whether associated with an AE)
All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following paragraphs.
Events listed in the table above that require reporting to Pfizer Safety on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an investigational product under study .  In particular, if the SAE is fatal or life-threatening, 
notification to Pfizer Safety must be made immediately, irrespective of the extent of available event information.  CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 58This time frame also applies to additional new (follow -up) information on previously  
forwarded reports.  In the rare situation that the investigator does not become immediately  
aware of the occurrence of an event, the investigator must report the event within 24 hours 
after learning of it and document the time of his/her first awareness of the event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF .  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causalit y.  An y information relevant to 
the event, su ch as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined by the sponsor to be serious will be reported by  the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology , and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject . In addition, each study  subject will be questioned about the 
occurrence of AEs in a nonleading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted b elow, and recorded on the CRF.
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 598.1.4. Time Period for Collecting AE/SAE Informati on
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  study -
related procedure and/or receiving investigational product) . All AEs are collected through 
and including Visit 5 (Month 7) .Additionally , SAEs are collected between Visit 5 (Month 
7) through Visit 6
(Month 12) , as elicited b y telephone .
In addition, any  AE occurring up to 48 hours after each subsequent blood draw ( ie, after 
Visit 5 [Month 7] and 
at the time of a diarrheal episode ) must be recorded on the CRF.
Diarrheal episode AEs must also be recorded on the CRF throughout the study .
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT S AE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .If a
nSAE is reported after subject Visit 6, all the 
requirements will appl y, including the respect of the reporting timelines as if the SAE 
occurred within the reporting period .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Nonserious AE s and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the fac ts 
(evidence) or arguments to suggest a causal relationship should be provided.  
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 60If the investigator does not know whether or not the investigational product caused the event, 
then the event will be handled as “related to investigational product” for repo rting purposes, 
as defined b y the sponsor.  If the investigator's causality  assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records.
In addition, if the investigator determines that an SAE is a ssociated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study  subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 61Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in stud y dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of any  of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A
nSAE is any  untoward medical occurrence at any  dose that:
Results in death;
Is life-threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 62Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediatel y life -threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as ser ious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
Medical device complain ts may  meet the SAE reporting requirement criteria (see the Medical 
Device Complaint Reporting Requirements section).  An incident is an y malfunction (ie, the 
failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly  or indirectl y, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deterioration in their state of health.  
A serio us injury  that can cause a serious deterioration in state of health can include:
A life -threatening illness, even if temporary  in nature;
A permanent impairment of a bod y function or permanent damage to a body 
structure; 
A condition necessitating medical or surgical intervention to prevent the above 
2bulleted items;
Examples: clinically  relevant increase in the duration of a surgical procedure; a 
condition that requires hospitalization or significant prolongation of existing 
hospitalization;
Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the manufacturer’s instructions for use;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
8.2.4. Hospitalization
Hospitalizati on is defined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visi t is assessed for medical importance.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 63Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a stud y (eg, for a procedure required by the stud y 
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as S AEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are m et, and the resulting appendectomy  should be recorded as treatment of the 
AE.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 648.3.Severity Assessment
GRADE If required on the AE page of the CRF, the investigator w ill use the adjectives MILD, 
MODERATE, SEVERE, or LIFE -THREATENING to describe the maximum intensity of the 
AE. For purposes of consistency, these intensity grades are defined as follows:
1 MILD Does not interfere with subject's usual function.
2 MODERATE Interferes to some extent with subject's usual function.
3 SEVERE Interferes significantly with subject's usual function.
4 LIFE -
THREATENINGLife-threatening consequences; urgent intervention indicated.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previous sections, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a subject 
presents with clinical signs/sy mptoms, such LFT results should be managed and followed as 
described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory
sample).  In rare instances, by  the time TBili elevations are detected, AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 65elevations in either AST OR AL T in addition to TBi li that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
oPreexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
oPreexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 × 
ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be 
assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as p ossible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory tests, detailed his tory, and physical assessment.
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase ,and acetaminophen drug and/or protein adduct levels .  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etio logy.  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 66collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, b iliary  tract) may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili ele vation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposur e to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact with 
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed during 
his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this informa tion to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 67Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  
In the case of a live birth, the struc tural integrit y of the neonate can be assessed at the time of 
birth.  I n the event of a termination, the reason(s) for termination should be specified and, if 
clinically  possible, the structural integrit y of the terminated fetus should be assessed b y gross
visual inspection (unless preprocedure test findings are conclusive for a congenital anomal y 
and the findings are reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal dem ise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of bi rth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of a n AE.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 68An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in th e study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.4. Medication Errors
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 24 
Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
8.4.4.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength.  
Medication errors include :
Medication errors involving subje ct exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Other examples include, but are not limited to:
The administration of expired investigational product;
The administration of an incorrect investigational product;
The administration of an incorrect dosage;
The administration of investigational product that has undergone temperature 
excursion from the specified storage range, unless it is determined by  the sponsor that 
the investigational product under question is acceptable for use.
Such medication errors occurring to a stud y subject are to be captured on the medication 
error page of the CRF, which is a specific version of the AE pag e.
In the event of a medication dosing error, the sponsor should be notified immediately .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 69Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are reco rded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
8.5.Medical Device Comp laint Reporting Requirements
All medical device complaints, regardless of whether the medical device complaint is 
associated with an AE, will be reported by  a member of unblinded site staff as described in the 
IP manual .  This includes potential incidents or malfunctions associated with the use of a 
medical device product.  An incident or malfunction is an event that might have led to death 
or serious deterioration in health, or if it occurred again might lead to death or serious 
deterioration in health.
Pfizer is to be notified of all medical device complaints within 24 hours of the investigator’s 
awareness of the event.
9. DATA ANALYSIS/STATIS TICAL METHODS
Themethodology  for summary  and statistical analy ses of the data collected in this study  is 
outlined he re and further detailed in a 
statistical analy sis plan(SAP) , which will be 
maintained by the sponsor. The SAP may modify  what is outlined in the protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition s or their 
analyses will also be reflected in a protocol amendment. Supplemental analyses of the 
primary , secondary , immunogenicity , and safety  data may  be performed as required for local 
regulatory  jurisdictions ( for example , anal yses by age, sex,ethnicity , risk status prior to 
vaccination ) and will be prespecified in the SAP. 
The SAP will be finalized prior to an y anal yses being undertaken.
9.1.Sample Size Determination
This study  is placebo -controlled, event
-driven, and randomized with a 1:1 randomization 
ratio be
tween subjects receiving C difficile vaccine and placebo.
With assumptions of a true adjusted VE of 6 6.5% after 3 doses of investigational product, 
66first primary  CDI cases (meeting case definition 1 in the per- protocol -3 population 
Section 2.1.1 and Section 9.2.1 ) will provide 89.8 % power to conclude true VE of >20% ,
taking into consideration 3interim analy ses (Section 9.5) during the study .  
The early  efficacy  stopping boundaries are based on a GS design65utilizing a single -binomial 
distribution, conditional on a total of 6 6 cases, assuming true VE of 66.5%, with 3interim 
analyses at 30
, 40 and 50 cases.65  The same gamma[ -2] alpha spending function that was 
used for the original statistical design is als o used for this modified statistical design.  
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 70As this is an event -driven and GS study , the total enrollment number may  vary  depending on 
the assumptions of incidence rate of the primary  endpoint, true VE , and potential earl y stop 
for efficacy  or futility . 
Update as Pa rt of Amendment 2 ( January 2019):
Based on the ongoing blinded review of pooled primary  CDI events, the annual CDI  
incidence rate in the placebo group may  be different from the assumed rate in the 
power calculation during the initial study  design. Additional enrol lment may  be 
needed in order to maintain the study  power of 90% (106 first primary  CDI cases in 
the final anal ysis) to reject the null hy pothesis of VE ≤20%. Assuming a true VE of 
60% after 3 doses of investigational product andthe true annual CDI rate in the 
placebo group of 0.552% to 0.516%, which is 8 to 14% lower than the previous ly
assumed 0.6% , an additional 1369 to 2566 subject smay be needed to ensure the 
requir ed number of first primary  CDI cases . 
In light of this, it is planned to enroll approximately 1700 additional subjects , giving a 
total of approximately  17,476 subjects . The pooled primary  CDI event rate for the 
total population will continu e to be monito red by  the study  team in a blinded manner 
and a further adjustment to enrol lment may  be required .
Update as Pa rt of Amendment 4 ( July2020 ):
The statistical design is being modified to perform all the anal yses with fewer cases 
than originall y planned.  Two(2)additional interim analy ses will be included based 
on the estimated disease rate from the blinded data review , and the assumption 
regarding true VE is modified to 68%, and is further adjusted to 66.5% after 3 doses 
of investigational product because ofthe impact of actual specificit y (99.1%) and 
sensitivity  (95.7%) of Pfizer’s cell cy totoxicity  neutralization assay .66  
The pooled primary  CDI event rate for the total population will continue to be 
monitored by  the study  team in a blinded manner and a further adjustment to 
enrollment may  be required.
As specified in Section 3.1, the pooled primary  CDI event rates in different a ge groups, 
inclusion criteria subgroups, CCI61subgroups ,and other baseline factors will be monitored in 
a blinded manner. Once the specified minimum numbers in each age group have been 
achieved, if a substantially higher pooled CDI eve
nt rate is observed in some subgroups, the 
intention may  be to stop enrollment in lower -risk subgroups and complete enrollment with 
the higher -risk subgroups thereafter. This is mainly  to help to achieve the targeted total 
number of firstprimary  cases in a timely  manner. As none of the potential adjustments will 
be based on the observed VEof the ongoing study, and the targeted total number of first 
primary  CDI cases will remain the same, the distribution of the test statistic for the primary  
endpoint under the null hypothesis will not be affected and no alpha adjustment will be 
required.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 71For the second primary  hypothesis test, it is expected that more than 66 cases for the final 
analysiswill occur after 2 or more doses because of the nature of the endpo int.  Any  
additional first primary  CDI cases occurring in the interval between Doses 2 and 3 will result 
in greater than 90% power 
to conclude true VE of>20% after 2 or more doses of vaccine 
assuming the vaccine first successfull y demonstrates VE of>20% following 3 doses of 
vaccine.
9.2.Efficacy Analysis
All of the following VEanalyses assume correct classification of suspected CDI  cases for all 
case definitions.
Five (5) anal ysis populations ( per-protocol -2, per -protocol - 3, mI TT -1, mI TT-2,and mITT-3) 
will be defined for VEanaly ses.
The per-protocol - 2 population will include all randomized subjects who received at 
least 2 doses of the investigational product to which they  were randomized and ha d 
no major protocol violations up to and including 14 day s after Dose 2.
The per-protocol - 3 population will include all randomized subjects who received all 
3doses of theinvestigational product to which they  were randomized and had no 
major protocol violations up to and including 14 days after Dose 3. 
The mITT -1population will include all randomized subjects who received at least 
1dose of investigational product.
The mITT -2 population will include all randomized subjects who received at least 
2 doses of investigational product. 
The mITT -3 population will include all randomized subjects who received all 3 doses 
of investigational product . 
The per-protocol -2 and per-protocol -3populations will be the primary  populations for 
efficacy  anal yses accounting for the time interval after dosing as given in Table 6and will be 
used for analy zing VEendpoints.  The mITT-1, mITT - 2, and mITT - 3 populations will be 
supportive populations for efficacy  anal yses and will be used 
for anal yzing VEendpoints 
from immediately or 14 day s after receipt of each dose of investigational product.
9.2.1. Analysis of the Primary Endpoint s
VE is defined as VE = 100 × (1 –IRR), where IRR is the infection rate ratio, the calculated 
ratio of first primary  CDI incidence between the C difficile vaccine group and the placebo 
group. VE iwill be evaluated separatel y after 3and after 2doses. The 2primary  efficacy  
hypotheses are (in order of fixed -sequence testing) :
1. H 03: VE 320% vs H a3: VE 3>20%, and
2. H 02: VE 220% vs H a2: VE 2>20% .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 72where H 0i and H ai represent null hy pothesis and alternative hy pothesis, and VE i(i = 2, 3) 
represents VE after at least 2 doses and after all 3 doses, respectively . For subjects with 
multiple primary  CDI cases, only  thefirst primary  case will contribute tothe VE calcul ation 
in each hypothesis test.
The primary  efficacy  hypotheses will be tested by  a 1-sided test for VE>20% by  a 
fixed -sequence testing procedure, with testing order of H03followed by H02using the 
approach described in Chan and Bohidar ,63accounting for follow -up time after vaccination.  
Statistical inference will be based on the lower alpha
-adjusted confidence interval (CI) for 
VE 3.and VE 2. 
If the stud y continues after all 3 of the interim analy ses, once 66 first primary  cases after 
3doses have accumulated for the final anal ysis, the hy pothesis test H03will be performed 
first, and the null hy pothesis H 03will be rejected if there are 
20 or fewer cases observed in 
the 
Cdifficile vaccine group ( corresponding to a 2- sided lower bound of 96.4% exact CI  
>20%) ,assuming equal follow -up times
.The lower bound of the 2-sided 96. 4% exact CI  
corresponds to 
α=0.018 (one-sided) used for final testing in a GSdesign with a gamma( -2) 
efficacy  boundary . Only if the hypothesis H 03is rejected, then h ypothesis testing for H 02will 
be performed, at the same significance level for VE 2for the final analysis.The statistical 
success criterion for H 02 also corresponds to the lower bound of the 2 -sided 96.4% CI  for VE 
being >20%. If there is failure to reject the hy pothesis H 03,the hy pothesis test H02will not be 
performed. 
The statistical anal ysis specifications for the primary  endpoints aresummarized in Table 6.
Table 6. Statistical Analysis Specifications for the Primary Endpoints
Prim ary
EndpointsTime Period for 
Case Accrual CDI Case 
Definition Analysis 
Population Hypothesis 
TestingaStatistical 
Testing M ethod
CDI incidence of a 
first primary
episode per 1000 
person -years of 
follow -upFrom 14 days after 
receipt of third 
dose of 
investigational 
product onwards1 Per-protocol-3
(primary)H03 Exact binomial, 
incidenc e rate 
CDI incidence of a 
first primary 
episode per 1000 
person -years of 
follow -upFrom 14 days after 
receipt of third 
dose of 
investigational 
product onwards1 mITT-3
(supportive)H03 Exact binomial, 
incidence rate 
CDI incidence of a 
first primary 
episode per 1000 
person -years of 
follow -upFrom immediately 
after receipt of 
third dose of 
investigational 
product onwards1 mITT-3
(supportive)H03 Exact binomial, 
incidence rate 
CDI incidence of a 
first primary 
episode per 1000 
person -years of 
follow -upFrom 14 days after 
receipt of second 
dose of 
investigational 
product onwards1 Per-protocol-2
(primary)H02 Exact binomial,
incidence rate 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 73Table 6. Statistical Analysis Specifications for the Primary Endpoints
Prim ary
EndpointsTime Period for 
Case Accrual CDI Case 
Definition Analysis 
Population Hypothesis 
TestingaStatistical 
Testing M ethod
CDI incidence of a 
first primary 
episode per 1000 
person -years of 
follow -upFrom 14 days after 
receipt of second 
dose of 
investigational 
product onwards1 mITT-2
(supportive)H02 Exact binomial,
incidence rate 
CDI incidence of a 
first primary 
episode per 1000 
person -years of 
follow -upFrom immediately 
after receipt of 
second dose of 
investi gational 
product onwards1 mITT-2
(supportive)H02 Exact binomial,
incidence rate 
Abbreviations: CDI = Clostridium difficile infection; mITT = modified intent -to-treat.
a.For the per -protocol populations, hypotheses H 02and H 03will be tested in the fixed order of H 03followed 
byH02.
9.2.1.1. Multiplicity Control for the Primary Endpoints
There are 2 primary  efficacy  hypotheses ; H03,followed b y H02,ifH03is rejected .The stud y 
will be considered successful if H 03 isrejected .
There are 2 sources of multiplicity  in the study . First, there are repeated analy ses of the 
primary  hypothesis H 03, at the interim and final analys es.Alpha adjustment due to the 
planned interim analyses is explained in Secti on 9.5 . The second source of multiplicity  is the 
existence ofmultiple primary  hypotheses. The overall ty pe I error rate for all primary  
hypotheses is 
controlled by  the fixed -sequence testing procedure as described in 
Section 9.2.1. Testing hypothesis H02will be considered as final anal ysisat the ty pe I error 
of 0.018 only if H 03is rejected and a decision is made to proceed to the final analysis. 
9.2.2. Analysis of the Secondary Endpoints
9.2.2.1. Analysis of the Secondary Efficacy Endpoints
The anal yses of the secondary  efficacy  endpoints will be performed based on a variet y of 
CDI case definiti ons, detailed in Section 2.1, after the primary  objectives are met . For the 
endpoints that combine data for subjects who fulfil
lcase definition 1 and subjects who fulfil l
case definition 3, or case definitions 2 and 4, each subject will contribute only once to the 
analysis.
In the evaluation of the efficacy  of 2doses of C difficile vaccine, onl y cases starting after the 
receipt o
f the second dose but prior to the rec eipt of the third dose of investigational product
will contribute to the VE calculation. 
In order to control overall Ty pe I error, and specifically  the Ty peI error for the evaluation of 
the secondary  objectives, an alpha level of 0.
018(one-sided) for the final analy sis is split 
equally  (the Bonferroni correction, alpha =
0.009, for each famil y evaluation) for the 
evaluation of the secondary  objectives between the 3-dose famil y and the 2 -dose family  
(at-least-2-dose/onl y-2-dose) , after primary  objectives are met .
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 74Furthermore, within each family, the endpoints will be evaluated sequentially; that is, the 
subsequent endpoint is evaluated only if the criteria are met for the previous endpoints.
The analysis and the success criteria for the secondary objective evaluation are outlined 
below:
•For evaluating C difficile vaccine in reducing the incidence of CDI cases, the lower 
limit (LL) of 98.2% CI (2-sided) for VE > 0.
•For evaluating the efficacy of Pfizer’s C difficile vaccine in reducing the severity of 
CDI in terms of the duration, the upper limit (UL) of 98.2% CI (2-sided) < 0 for the difference in mean duration of CDI between the vaccine group and the control group.
•For evaluating the efficacy of Pfizer’s C difficile vaccine in reducing the severity of 
CDI in terms of the risk ratio, the UL of 98.2% CI (2-sided) < 1.0 for the ratio of the proportion of subjects experiencing CDI who have a non-protocol-related medically attended visit in the vaccine group to the proportion of the subjects in the controlgroup.
 
 
 
 
 
 
 
 
 
 
 
9.4. Safety Analysis
The safety population will include all subjects who receive at least 1 dose of investigational 
product. The safety population for reactogenicity analysis after each dose will includesubjects who received that dose and have e-diary information available. For safety analysis, subjects will be analyzed according to the investigational product received.CCI
CCI
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 75AEs will be categorized according to Medical Dictionary  for Regulatory  Activities 
(MedDRA) and will be summarized by  vaccine group. All summaries of AEs will show the 
number and percentage of subjects experiencing at least 1 event and the number of events for 
each vaccine group. Two (2)-sided 95% CIs based on the Clopper -Pearson method will be 
presented for (S)AE percentages.
A 3-tier approach will be used to summarize AEs. Under this approach, AEs are classified 
into 1 of 3 tiers:
Tier 1 events: These are prespecified events of clinical importance and are maintained 
in a list in the product’s Safety Review Plan.
Tier 2 events: These are events that ar e not tier 1 but are “common.” A MedDRA 
preferred term is defined as a tier 2 event if there is an incidence of at least 1% in any  
vaccine group.
Tier 3 events: These are events that are neither tier 1 nor tier 2 events.
The Miettinen and Nurminen method64will be used to derive the 95% CI for the risk 
difference between C difficile vaccine and placebo for the above tier 1 and tier 2 events. The 
p-value from Miettinen and Nurminen method will also be provided for tier 1 events.
9.4.1. Reactogenicity 
The proportion of subjects reporting local reactions at the injection site and sy stemic events 
on any  day within the 
7-day period after vaccination will be descriptivel y summarized by 
vaccine group.
Sever ities of local reactions and sy stemic events reported after each vaccination will also be 
descriptivel y summarized by vaccine group. Two (2) -sided 95% CIs based on the 
Clopper -Pearson method will be presented with the proportions. 
9.5. Interim Analysis
Three (3)planned formal interim analy ses will be performed by the independent statistical 
team (IST) to assess whether there is overwhelming efficacy  or futility  with respect to the 
end-of- study  success criterion.
The first, second ,and third interim anal yses areplanned after 30, 40, and 50first primary  
CDI cases have occurred from 14 day s after receipt of the third dose of investigational 
product , respectivel y. The data cutoff date will be the calendar date of the confirmed 30th, 
40th,or 50th casesof first primary  CDI occurring 14 day s after the third dose by the central 
laboratory . Only the first primary  efficacy  endpoint will be examined. The statistical 
hypotheses testing (
H03) will be performed on interim data ; H02will be tested if H 03 is 
rejected and a decision is made to proceed the final analy sis
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 76The early  efficacy  stopping boundary  is derived on a GS design65(utilizing a single -binomial 
distribution, conditional on the total number of 66cases, with 3 interim analy ses at 45 % 
[30 out of 66], 61% [40 out of 66], and 76% [ 50 out of 66] of information and a gamma [ -2]
alpha spending function).
The GSdesign from EAST (software package for clinical trial design) is based on normal 
approximation to binomial distribution, and EAST was used as a starting point to calculate 
GS design boundaries. Those were later converted into discrete boundaries (expressed as 
number s
of cases rather than proportions of cases coming from a vaccine group, given the 
total number of cases).
If there are 6 or fewer cases obser ved in the C difficile vaccine group out of a total of 30 first
primary  cases (point estimate of VE ≥75.0% and corresponding to a lower bound of 2-sided
98.8% exact CI  >20%) , the null hypothesis in H 03will be rejected ,the C difficile vaccine will 
be deemed effica cious , and a full anal ysis of the data will be conducted . 
If there are 9 or fewer cases observed in the C difficile vaccine group out of a total of 40 first 
primary  cases in the second interim analy
sis (point estimate of VE ≥71.0% and 
corresponding to a lower bound of 2- sided 98.8% exact CI  >20%), the null hy pothesis in H 03
will be rejected, the C difficile vaccine wil l be deemed efficacious, and a full analy sis of the 
data may  be conducted.  
If there are 13 or fewer cases observed in the C difficile vaccine group out of a total of 
50first primary  cases in the third interim anal ysis (point estimate of VE ≥64.9% and 
corresponding to a lower bound of 2- sided 98.2% exact CI  >20%), the null hy pothesis in H 03
will be rejected, the C difficile vaccine will be deemed efficacious, and a full analy sis of the 
data may  be conducted.  
Of note, using the lower bound of a 2- sided 98.8 % CI  corresponds to α=0.006 (one -sided) 
used for the first and second interim analy ses; the lower bound of a 2 -sided 98.2% CI  
correspond sto α=0.009 (one-sided) for the third interim anal ysis.
The probabilit iesof stopping the trial for success are44.3% at interim analy sis 1(ie, observe 
6cases in the 
C difficile vaccine group) ,15.0% at interim analy sis 2 (ie, observe  9cases in 
the C difficile vaccine group ), and 17.1% at interim analy sis 3 (ie, observe 13cases in the 
Cdifficile vaccine group) if the true VEis 70%. 
Study  futility  at each interim analy sis will be evaluated based on the pre -identified case split 
(C difficile vaccine vs placebo) b y anal ysis of conditional power (CP) approach. The 
conditional probability  of study  success at the 
final anal ysis with observed VE of at least 
59.6% (19 out of 66 cases) is calculated based on an assumed case split in the C difficile
vaccine group and the assumption that an adjusted true VE of 66.5% remains for the rest of 
the study .The case split for futility  is 11 versus 19 for IA1(corresponding to a CP cutoff of 
50% at 30 cases) , 13 versus 27 for IA2 (corresponding to a CP cutoff of 60% at 40 cases) ,
and 16 versus 34 for IA3 (corresponding to a CP cutoff of 60% at 50 cases).
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 77These futility  boundaries may  be subject to change to reflect subsequent program -related 
decisions by  the Sponsor.  
The probability  of stopping the trial because of futility is 6.6% at interim analy sis 1 
(ie, observe ≥1 1cases in the C difficile vaccine group) , 5.8% atinterim analy sis 2
(ie,observe ≥13cases in the C difficile vaccine group )
,and 2.0% at interim anal ysis 3 
(ie,observe ≥16 cases in the C difficile vaccine group ) ,if the true VEis 70%.
The overall probability  of success is at least 84.8% if the true VEis 70%.
Addition alfutility  assessments for the study  might be carried out at the time of 
external data 
monitoring committee ( E-DMC ) meetings. Full details of the futility  assessment will be 
provided in the SAP.
There is no impact on the overall 
type I error rate for futility  anal yses performed for the 
study .
Additional design operating characteristics (stopping boundary  based on the number of cases 
observed in the C difficile vaccine gr oup; the probabilities of stopping for efficacy  and 
futility  given assumed various VEs with a 1:1 randomization ratio) are listed in Table 7.
Table 7. Statistical Design Operating Characteristics
Interi m Analysis #1
(Total Cases = 30)Interi m Analysis #2
(Total Cases = 40)Interi m Analysis #3
(Total Cases = 50)Final Analysis
(Total Cases = 66)
Vaccine 
Efficacy 
(%)Probability 
of Success
(Cases in 
Cdifficile
Vaccine 
Group 6)Probability 
of Failure
(Cases in 
Cdifficile
Vaccine 
Group 
11)Probability 
of Success
(Cases in 
Cdifficile
Vaccine 
Group 9)Probability 
of Failure
(Cases in 
Cdifficile
Vaccine 
Group 
13)Probability 
of Success
(Cases in 
Cdifficile
Vaccine 
Group 13)Probability
of Failure
(Cases in 
Cdifficile
Vaccine 
Group 
)Probability 
of Success 
(Cases in 
Cdifficile
Vaccine 
Group 
20)Probability 
of Failure 
(Cases in 
Cdifficile
Vaccine 
Group 21)Overall 
Probability 
of Success
0
20
50
600.0007
0.0047
0.0838
0.20390.9506
0.8512
0.4152
0.21460.0002
0.0017
0.0397
0.09090.0416
0.1066
0.2032
0.14900.0003
0.0029
0.0721
0.14240.0050
0.0211
0.0709
0.05570.0002
0.0033
0.0739
0.11340.0014
0.0085
0.0410
0.03000.0014
0.0126
0.2696
0.550 7
70 0.4427 0.0656 0.1496 0.0583 0.1711 0.0202 0.0845 0.0080 0.8479
80 0.7765 0.0067 0.1207 0.0063 0.0730 0.0015 0.0149 0.0003 0.985 2
Note: Assumes 95.7% assay sensitivity and 99.1% assay specificity.  Assumes equal follow -up times between 
vaccine groups.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 78Should the actual amount of information observed at interim anal ysis be more than the 
planned information capture foreach interim analy sis, the first targeted primary  cases will be 
used for the anal ysis. 
9.6.Data Monitoring Committee
This study  will use an E -DMC . 
The E
-DMC will be responsible for ongoing monitoring of VE, futility ,and safet y of subjects 
in the s tudy according to the charter. The E -DMC may  review unblinded data during closed 
meeting sessions; however, the sponsor will remain bl inded and will not be permitted access 
to the randomization assignments until the database is locked.
The E- DMC will review efficacy /futility  and safety  data at defined intervals as s pecified in 
the charter. The E -DMC may  conduct additional meetings to re view safety  data at other time 
points during the stud y, at its discretion, or at the request of the sponsor. In addition, as 
determined b y the sponsor clinician, the E -DMC may  meet on an ad hoc basis to evaluate 
any SAEs related to vaccination, or related AEs that may  jeopardize further subject 
participation, in order to determine that the study  may  be continued safel y.
The E- DMC will work in association with the I ST in order to conduct both the safet y and 
futility /efficacy  evaluations. The I ST will inclu de statistician(s) and programmer(s) who are 
independent of the sponsor and who have unrestricted access to the randomization 
assignments during the st udy. The I ST will perform statistical analy sis and prepare 
unblinded data and reports to provide to the E-DMC for assessment in accordance with the 
E
-DMC charter. The IST will report the outcome of the planned futility  checks (onl y 
whether the futility  rule has been passed or not) to the sponsor and the E- DMC separatel y.
After each meeting, the E -DMC will m ake recommendations that may include the following: 
continue the study  with or without modification, pause or stop vaccination for safet y or other 
reasons, or pause or stop the study  for efficacy  or futility  (assessed at an efficacy /futility  
meeting onl y).
The recommendations made b y the E -DMC to alter the conduct of the study  will be 
forwarded to Pfizer for final decision. Information on the current efficacy  cases (number s
occurring in the C difficile vaccine and placebo groups) will not be disclosed until a decision 
is made to permanentl y stop the study .Pfizer will forward such decisions, which may  
include summaries of aggregate anal yses of endpoint events and of safet y data that are not 
endpoints, to regulatory  authorities, as appropriate.
10.QUALITY CONTR OL AND QUALITY ASSUR ANCE
Pfizer or its agent will conduct periodic monitoring visits during stud y conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs areaccur ate.  The investigator and institution will 
allow Pfizer monitors/auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.  This verification may  also occur 
after stud y completion.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 79During study  conduct and/or after study  completion, the investigator site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropriate regula tory 
authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject's medi cal records.  The investigator will promptl y provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and c omment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regula tory 
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y
,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring that they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest t hat the 
data contained on the CRFs aretrue. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry .
In most cases, the source documents are the hosp ital or the ph ysician subject chart.  In these 
cases , data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site an d at Pfizer that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8011.2. Record Retention
To enable evaluations and/or inspections/ audits from regulatory  authorities or Pfizer, the 
investigat or agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
ICDs, copies of all CRFs, safet y reporting forms, source documents, and detailed records of 
treatment disposition, and adequate documentation of relevant correspondence ( eg,letters, 
meeting minutes, and telephone call reports).  The records should be retained by  the 
investigator according to the ICH guidelines, according to local regulations, or as specified in 
the c linical study agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, reloc ation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer.
Investigator records must be kept for a minimum of 15 y ears after completion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requireme nts have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, ICDs, and other relevant documents, eg,recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator f ile.  Copies of IRB/EC approvals should be forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guideline for G ood Clinical Practice , and the Declaration of 
Helsinki .
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in an yreports, publications, or other disclosures, except where
required b y law.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 81When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
name s, address es, and other identifiable data will be replaced b y numerical code sbased o na 
numbering s ystem provided by  Pfizer in order to de -identify  study  subject s . The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’s numerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .
The informed consent document s used during the informed consent process and an y subject 
recruitment materials 
must be reviewed and approved by  Pfizer , appro ved by  the IRB/EC
before use ,
and available for inspection.
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before any  study -specific activity  is performe d. The investigator 
will retain the original of each subject's signed consent document .
12.4. Reporting of S
afety Issues and S er ious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that 
might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer s hould be informed immediately .
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjec ts against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in a Member State
End of t rial in a Member State of the European Union is defined as the time at which it is 
deemed that a sufficient number of subjects have been recruited and completed the study  as 
stated in the regulatory  application (i e,clinical trial application [CTA ]) and ethics application 
in the Member State.  Poor recruitment (r ecruiting less than the anticipated number in the 
CTA) by  a Member State is not a reason for premature termination but is considered a 
normal conclusion to the study  in that Member State.
13.2. End of Trial in A llOther Participating Countries
End of trial in all other participating countries is defined as database lock.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8214.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC , orinvestigational product safety problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
Cdifficile vaccine at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 28 day s.  As directed by  Pfizer, all study  materials must be collected 
and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical trial results through posting the 
results of stud ies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of f inal collection of data for the primary outcome, whether the clinical study  
concluded according to the pre specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 83www.pfizer.com
Pfizer posts Public Disclosure Synopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.cl inicaltrials.gov.
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the 
principal investigator (PI) of the results of the study based on information collected or 
generated b y the 
PI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure aga inst inadvertent disclosure of confidential i nformation or unprotected 
inventions, 
the investigator will provide Pfizer an opportunity  to review any  proposed 
publicati on or other t ype of disclosure of the results of the s tudy (collectively , “publication”) 
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 day s before 
it is submitted 
for publication or other wise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 day s.
The i nvestigator will, on request, remove an y previously  undisclose d confidential 
information 
before disclosure, except for any  study-or Pfizer product -related information 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results.
If the study  is part of a multi centerstudy , the investiga tor agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent 
publications 
bythe PI will reference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of co mpletion or termination of the s tudy at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the study, the i nstitution will co mply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www
.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigator s, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA will control as to all other 
issues.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8416.REFERENCES
1. Guerr ant RL , Hughes JM, L ima NL, Crane J . Diarrhea in developed and developing 
countries: magnitude, special settings, and etiologies. Rev Infect Dis.
1990;12( suppl 1):S41 -S50.
2. Kelly  CP, Pothoulakis C, L aMont JT. Clostridium difficile colitis. N Engl J Med.
1994;330(4):257 - 262.
3. Kyne L, Kell y CP. Prospects for a vaccine for 
Clostridium difficile . BioDrugs .
1998;10(3):173 -
181.
4. McFarland LV. Epidemiology  of infectious and iatrogenic nosocomial diarrhea in a 
cohort of general medicine patients. Am J Infect Control .1995;23(5):295 -
305.
5. Magill SS, Edwards JR, Bamberg W, et al ; for the Emerging Infections Program 
Healthcare -Associated Infections and Antimicrobial Use Prevalence Survey  Team . 
Multistate point -prevalence survey  of health care –associated infections. N Engl J Med .
2014;370(13):1198 -1208.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium 
difficile infection in adults: 2010 update by  the Society  for Healthcare Epidemiology  of 
America (SHEA) and the I nfectious Diseases Society of America (IDSA). 
Infect Cont 
Hosp Epidemiol .2010;31(5):431 -455.
7. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile -associated disease: 
old therapies and new strategies. Lancet Infect Dis .2005;5(9):549 -
557.
8. Kuehne SA, Collery  MM, Kelly  M
L, Cartman ST, Cockay ne A, Minton NP . 
Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium 
difficile strain. 
J Infect Dis. 2014;209(1):83 -86.
9. Voth DE, Ballard JD. 
Clostridium difficile toxins: mechanism of action and role in 
disease. Clin Microbiol Rev .2005;18(2):247 -263.
10. Sunenshine RH, McDonald L C. Clostridium difficile -
associated disease: new challenges 
from an established pathogen. Cleve Clin J Med .2006;73(2):187 -197.
11.
Leffler DA, L amont JT. Clostridium difficile infection. N Engl J Med.
2015;372(16):1539 -1548.
12. Bartlett JG. Antibiotic -associated diarrhea. 
N Engl J Med. 2002;346(5):334 -339.
13. Mayo Clinic Staff. Diseases & c onditions: C.difficile infection. 
http://www.may oclinic.org/diseases -conditions/c -difficile/basics/sy mptoms/con -
20029664.  16 July  2013.  Accessed 27 February  2016.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8514. Bauer MP, Notermans DW, van Benthem BH B, et al; for the ECDI S Study Group. 
Clostridium difficile infection in Europe: a hospital- based survey . Lancet .
2011;377(9759):63 - 73.
15. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile
infection. Clin Infect Dis. 2008;46( suppl 1):S12 -S18.
16. Pepin J, Valiquette L . Cossette B. Mortalit y attributable to nosocomial Clostridium 
difficile –associated disease during an epidemic caused by  a hy pervirulent strain in 
Quebec. Can Med Assoc J .2005;173(9):1037 -
1041.
17.
Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in 
long-term care facilities: a review. J Am Geriatr Soc.2010;58(8):1556 -1564.
18.
Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin 
Infect Dis .2008;46( suppl 1):S32 -S42.
19. Louie TJ, Miller MA, Mullane KM, et al ; for the OPT -80-003 Clinical Study  Group . 
Fidaxomicin versus vancom ycin for Clostridium difficile infection. 
N Engl J Med.
2011;364(5):422 -431.
20. Kyne L, Warny  M, Qamar A, 
Kelly  CP. Association between antibody  response to toxin 
A and protection against recurrent Clostridium difficile diarrhoea. Lancet .
2001;357(9251):189-193.
21. Debast SB, Bauer MP, Kuijper EJ; on behalf of the Committee . European Society  of 
Clinical Microbiology  and I nfectious Diseases: update of the treatment guidance 
document for Clostridium difficile infection. Clin Microbiol Infect. 2014;
20(suppl 2):1-26.
22. Ricciardi R, Rothenberger DA, Madoff RD, Baxter N . Increasing prevalence and 
severit y of Clostridium difficile colitis in hospitalized patients in the United States. Arch 
Surg. 2007;142(7):624 -131.
23. Khanna S, Pardi DS. The growing incidence and severit y of Clostridium difficile
infection in inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol
.
2010;4(4):409 -416.
24. Shivashankar R, Khanna S, Kammer PP, et al. 
Clinical factors associated with 
development of severe -complicated Clostridium difficile infection. Clin Gastroenterol 
Hepatol .2013;11(11):1466 -1471.
25. Hensgens MP M, Goorhuis A, Dekkers OM, 
van Benthem GHB, Kuijper EJ. All- cause 
and disease -specific mortality  in hospitalized patients with C lostridium difficile
infection: a multicenter cohort study . Clin Infect Dis. 2013;56(8):1108 - 1116.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8626. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbay a A, Haider S . Clinical and 
economic burden of Clostridium difficile infection in Europe: a s ystematic review of 
healthcare -facility -acquired infection. J Hosp Infect .2012;81(1):1 -14.
27. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the 
United States. N Engl J Med. 2015;372(9):825 -834.
28. Dubberke E. Clostridium difficile infect ion: the scope of the problem. J Hosp Med.
2012;7( suppl 3):S1-S4.
29. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin 
Infect Dis .2012;55( suppl 2):S88 -S92.
30. Gerding DN, Lessa FC. The epidemiology  of Clostridium difficile infection inside and 
outside health care institutions. Infect Dis Clin North Am .2015;29(1):37 -50.
31. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi -institutional 
outbreak of Clostridium difficile –associated diarrhea with high morbidit y and mortality . 
N Engl J Med
.2005;353(23):2442-2449.
32. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene–variant strain 
of Clostridium difficile . N Engl J Med. 2005;353(23):2433 -2441.
33. Pepin J, Valiquette L , Alary  ME, et al. Clostridium difficile -associated diarrhea in a 
region of Quebec from 1991 to 2003: a changing pattern of disease severity . Can Med 
Assoc J .2004;171(5):466 -472.
34. Gerding DN. Clindam ycin, cephalosporins, fluoroquinolones, and Clostridium difficile –
associated diarrhea: t
his is an antimicrobial resistance problem. Clin Infect Dis.
2004;38(5):646 -648.
35. Kyne L, Farrell RJ, Kelly  CP. Clostridium difficile . Gastroenterol Clin North Am . 2001;
30(3):753-777.
36. Gerding DN, Johnson S. Management of Clostridium difficile infection: th inking inside 
and outside the box. Clin Infect Dis. 2010;51(11):1306-1313.
37. Mattila E, Uusitalo -Seppala R, Wuorela M, et al. Fecal transplantation, through 
colonoscop y, is effective therap y for recurrent Clostridium difficile infection. 
Gastroenterology . 2012;142(3):490 - 496.
38. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for 
recurrent 
Clostridium difficile . N Engl J Med. 2013;368(5):407 - 415.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8739. Anony mous. Guidance for industry : enforcement policy  regarding investigational new 
drug requirements for use of fecal microbiota for transplantation to treat Clostridium 
difficile infection not responsive to standard therapies. US Food and Drug 
Administration (FDA), US Department of Health and Human Services. 
https://www.fda.gov/media/86440/download.  July  2013. Accessed 27 February  2016.
40. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium difficile
infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol .
2014;35(6):628 -
645.
41. Kyne L, Warny  M, Qamar A, 
Kelly  CP. Asymptomatic carriage of Clostridium difficile
and serum levels of IgG antibody  against toxin A. N Engl J Med. 2000;342(6):390 -397.
42. Warny  M, Vaerman JP, Avesani V, 
Delmee M . Human antibody  response to 
Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun
.
1994;62(2):384 -389.
43. Gupta SB, Mehta V, Dubberke ER, et al. Antibodies to toxin B are protective against 
Clostridium difficile infection 
recurrence. Clin Infect Dis . 2016;63(6):730 -734.
44. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed 
against toxins A and B prevent Clostridium difficile -induced mortality  in hamsters. 
Infect Immun .2006;74(11):6339 -
6347.
45. Torres JF, Ly erly DM , Hill JE, Monath TP . Evaluation of formalin -inactivated 
Clostridium difficile vaccines administered b y parenteral and mucosal routes of 
immunization in hamsters. Infect Immun .1995;63(12):4619
-4627.
46. Giannasca PJ, Zhang ZX, L ei WD, et al. Serum antitoxin a ntibodies mediate sy stemic 
and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun.
1999;67(2):527 -538.
47. Lowy I, Mol rine DC, Leav BA, et al. Treatment with monoclonal antibodies against 
Clostridium difficile toxins. 
N Engl J Med. 2010;362(3):197 -205.
48. Merck & Co., Inc. Pivotal Phase 3 studies of bezlotoxumab, Merck’s investigational 
antitoxin to prevent Clostridium difficile infection recurrence, met primary  endpoint. 
https://www.mrknewsroom.com/newsroom/news -releases/news -details/ 2015/Pivotal -
Phase -3-Studies -of-Bezlotoxumab -Mercks -Investigational -Antitoxin -to-Prevent -
Clostridium -Difficile -Infection -Recurrence -Met-Primary -Endpoint/default.aspx .  
September 2015.  Accessed 24 March 2016.  
49. Demarest SJ, Hariharan M, Elia M, et al. Neut ralization of Clostridium difficile toxin A 
using antibody combinations. MAbs .2010;2(2):190 -198.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8850. Zhou Y, Burnham CA D, Hink T, et al. Phenoty pic and genot ypic analysis of 
Clostridium difficile isolates: a single -center study . J Clin Microbiol .
2014;52(12):4260 -4266.
51. Greenberg RN, Marbury  TC, Foglia G, 
Warn y M.  Phase I dose finding studies of an 
adjuvanted Clostridium difficile toxoid vaccine. Vaccine .2012;30(13):2245-2249.
52. Kotloff KL, Wasserman SS, L osonsky  GA, et al.  Safety and immunogenici ty of 
increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.  
Infect Immun .2001;69(2):988 -995.
53. Aboudola S, Kotloff KL, Ky ne L, et al.  Clostridium difficile vaccine and serum 
immunoglobulin G antibody  response to toxin A.  Infect Immun .2003;71(3):1608 -1610.
54. Ghose C, Kelly  CP. The prospect for vaccines to prevent Clostridium difficile infection.  
Infect Dis Clin North Am .2015;29
(1):145-162.
55. Anony mous. Study  of candidate Clostridium difficile toxoid vaccine (Cdiffense) i
n 
subjects at risk for C difficile infection. Sanofi Pasteur Inc. ClinicalTrials.gov. 
https://www.clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED].   December 2015. Accessed 
27February  2016.
56. Tian JH, Fuhrmann SR, Kluepfel -Stahl S, Carman RJ, Ellingsworth L , Flyer DC.  A 
novel fusion protein containing the receptor binding domains of C.difficile toxin A and 
toxin B elicits protective immunity  against lethal toxin and spore challenge in 
preclinical efficacy  models. Vaccine .2012;30(28):4249-4258.
57. Anony mous. Dose -confirmation, immunogenicity  and safet y stud y of the Clostridium 
difficile vaccine candidate VLA84 in healthy  adults aged 50 y ears and older. Phase II 
study . Valneva Austria GmbH. ClinicalTrials.gov. 
https://www.clinicaltrials.gov/ct2/show /[STUDY_ID_REMOVED].   October 2015.  Accessed 
27February  2016.
58. Sheldon E, Kitchin N, Peng Y, et al. A phase 1, placebo -controlled, randomized study  
of the safet y, tolerability , and immunogenicit y of a Clostridium difficile vaccine 
administered with or without a luminum hy droxide in healthy  adults. Vaccine .
2016;34(18):2082 -2091.
59. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time.  
Scand J Gatroenterol .1997;32(9):920
-924.
60. Miller MA, L ouie T, Mullane K, et al. Derivation and validation of a simple clinical 
bedside score (ATLAS) for Clostridium difficile infection which predicts response to 
therap y. BMC Infect Dis .2013;13:148.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 8961. Charlson ME, Pompei P, Ales KL, MacKenzie CR . A new method of classify ing 
prognostic comorbidity  in longitudinal studies: development and validation. J Chronic 
Dis. 1987;40(5) :373-383.
62. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research 
(CBER). Guidance for I ndustry: T oxicity G rading Scale for Healthy Adult and 
Adolescent V olunteers E nrolled in Preventive V accine Clinical Trials. Rockville, MD: 
CBER; September 2007.
63. Chan I S, Bohidar NR. Exact power and sample size for vaccine efficacy  studies. 
Commun Stat Theory .1998;27:1 305-1322.
64. Miettinen O, Nurminen M. Comparative anal ysis of two rates. Stat Med
.
1985;4:213-226.
65. Jennison C, Turnbull BW. Group Sequential Methods With Applications to Clinical 
Trials. New York , NY : Chapman & Hall; 2000.
66. Lachenbruch PA.Sensitivity , specificity , and vaccine efficacy . Control Clin Trials .
1998; 19:569 -
574.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 90Appendix 1.Abbreviations
Thefollowing is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
AE adverse event
AlOH aluminum hy droxide
ALT alanine aminotransferase
AST aspartate aminotransferase
ATLAS age, treatment with sy stemic antibiotics during Clostridium difficile
infection therap y, leukocy te count, serum albumin, and serum creatinine
CBER Center for Biologics Evaluation and Research
CCI Charlson C omorbidity  Index
CDI Clostridium difficile infection
CE Conformité Européenne
CI confidence interval
CK creatine kinase
CP conditional power
CRA clinical research associate
CRF case report form
CSA clinical study  agreement
CT clinical trial
CTA clinical trial application
DILI drug-induced liver injury
DU dispensable unit
EC ethics committee
e-diary electronic diary
E-DMC external data monitoring committee 
EDP exposure during pregnancy
ELISA enzy me-linked immunosorbent assay
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States)
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GMFR geometric mean fold rise
GS group -sequential
HIV human immunodeficiency virus 
IB investigator 'sbrochure
ICD informed consent document 
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 91Abbreviation Term
ICH International Conference on Harmonisation
ID identification
IgG immunoglobulin G
IND investigational new drug application
INR international normalized ratio
IP investigational product
IRB institutional review board
IRR infection rate ratio
IRT interactive response technology
IST independent statistical team
IUD intrauterine device
IWR interactive Web -based response
LFT liver function test
LL lower limit
mAb monoclonal antibody
MedDRA Medical Dictionary  for Regulatory  Activities
mITT modified intent- to-treat
N/A not applicable
PCD primary  completion date
PCR polymerase chain reaction
PFGE pulsed-field gel electrophoresis
PI principal investigator 
PT prothrombin time 
SAE serious adverse event
SAP statistical analy sis plan
SRM study  reference manual
SRSD single reference safet y document
TBili total bilirubin
TcdA Clostridium difficile toxin A
TcdB Clostridium difficile toxin B
UL upper limit
ULN upper limit of normal
US United States
VE vaccine efficacy
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 92Appendix 2. Bristol Stool Chart

PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 93Appendix 3.France Appendix
This appendix applies to study  sites located in France.
1. GCP Training
Prior to enrollment of any  subjects, the investigator and any  subinvestigators will complete 
the Pfizer -provided Good Clinical Practice training course (“Pfizer GCP Training”) or 
training deemed equivalent by  Pfizer. Any investigators who later join the study will 
complete the Pfizer GCP Training or equivalent before performing study-related duties. For 
studies of applicable duration, the investigator and subinvestigators will complete Pfizer GCP 
Training or equivalent every  three y ears during the term of the study, or more often if there 
are significant changes to the ICH GCP guidelines or course materials.
2. Investigational Product
No subjects or third -party  payers will be charged for investigational product.
PF-06425090 ( Clostridium difficile Vaccine)
B5091007
Final Protocol Amendment 4, 28 Sept. 2020
PFIZER CONFIDENTIAL
Page 94Appendix 4.Japan Appendix
The following supplementary  text should be read in conjunction with the B 5091007 protocol:
An oral temperature of 37.5C meets the definition of a current febrile illness in the 
criteria for temporarily  delay ing vaccine administration described in Section 4.3 for 
subjects enrolled in Japan.
For the 2ndbulleted part of inclusion criterion 4, it is clarified that in Japan, subjects may 
be enrolled if, in the pre vious 12 months, they  have had at least 2 emergency  room visits 
for urgent or acute care.
For the 3rdbulleted part of inclusion criterion 4, (under protocol amendments 1, 2, and 3) 
it is clarified that in Japan that “primary  and/or secondary  care visits” may  have been 
undertaken in an y type of healthcare facilities (primary , secondary  [or tertiary ]) for care 
directed b y a ph ysician.  Note; Pharmacy  and/or mental health visits do not count toward 
the 10 outpatient visits required under this criterion.
'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	




 
'RFXPHQW 7LWOH! "#$"%&%'()%$$"*)'*%+,-"*% ").")&
$,'*"* (/*0(%".$/("(!"",0 "(0'*(%$"),$,(0%$% (),*,/+*,,,$".,'",'*/$( 0") %1"'*%$*")
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
& &	66#
 
7 PPD